24 March 2022
EMA/CHMP/125434/2022
Human Medicines Division

Committee for medicinal products for human use (CHMP)

Draft agenda for the meeting on 21-24 March 2022

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

21 March 2022, 09:00 – 19:30, room 1C

22 March 2022, 08:30 – 19:30, room 1C

23 March 2022, 08:30 – 19:30, room 1C

24 March 2022, 08:30 – 15:00, room 1C

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction 7

1.1. Welcome and declarations of interest of members, alternates and experts 7

1.2. Adoption of agenda 7

1.3. Adoption of the minutes 7

2. Oral Explanations 7

2.1. Pre-authorisation procedure oral explanations 7

2.1.1. betulae cortex dry extract (5-10: 1); extraction solvent: n-heptane 95% (w/w) - Orphan - EMEA/H/C/005035 7

2.1.2. budesonide, micronised - Orphan - EMEA/H/C/005653 7

2.1.3. capmatinib - EMEA/H/C/004845 8

2.2. Re-examination procedure oral explanations 8

2.3. Post-authorisation procedure oral explanations 8

2.3.1. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0109 8

2.4. Referral procedure oral explanations 8

3. Initial applications 8

3.1. Initial applications; Opinions 8

3.1.1. amifampridine - EMEA/H/C/005839 8

3.1.2. leuprorelin - EMEA/H/C/005034 9

3.1.3. ciltacabtagene autoleucel - PRIME - Orphan - ATMP - EMEA/H/C/005095 9

3.1.4. tixagevimab / cilgavimab - EMEA/H/C/005788 9

3.1.5. arimoclomol - Orphan - EMEA/H/C/005203 9

3.1.6. doxorubicin - EMEA/H/C/005320 9

3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable) 10

3.2.1. doxorubicin hydrochloride - EMEA/H/C/005330 10

3.2.2. ertapenem - EMEA/H/C/005815 10

3.2.3. ganirelix - EMEA/H/C/005641 10

3.2.4. mosunetuzumab - Orphan - EMEA/H/C/005680 10

3.2.5. melphalan flufenamide - Orphan - EMEA/H/C/005681 10

3.2.6. mitapivat - Orphan - EMEA/H/C/005540 11

3.2.7. valoctocogene roxaparvovec - Orphan - ATMP - EMEA/H/C/005830 11

3.2.8. eptacog beta (activated) - EMEA/H/C/005655 11

3.2.9. sitagliptin / metformin hydrochloride - EMEA/H/C/005850 11

3.2.10. sugammadex - EMEA/H/C/005760 11

3.2.11. tezepelumab - EMEA/H/C/005588 12

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable) 12
3.3.1. tabelecleucel - PRIME - Orphan - ATMP - EMEA/H/C/004577 12
3.3.2. abaloparatide - EMEA/H/C/005928 12
3.3.3. spironolactone ph. eur. - EMEA/H/C/005535 12
3.3.4. miglustat - Orphan - EMEA/H/C/005695 12
3.3.5. pirfenidone - EMEA/H/C/005862 12
3.3.6. cipaglucosidase alfa - Orphan - EMEA/H/C/005703 13
3.3.7. sugammadex - EMEA/H/C/005935 13
3.3.8. infigratinib - Orphan - EMEA/H/C/005361 13
3.3.9. vadadustat - EMEA/H/C/005131 13
3.4. Update on on-going initial applications for Centralised procedure 13
3.4.1. dengue tetravalent vaccine (live, attenuated) - Article 58 - EMEA/H/W/005362 13
3.4.2. dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/005155 13
3.4.3. iodine (131I) omburtamab - Orphan - EMEA/H/C/005499 14
3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004 14
3.6. Initial applications in the decision-making phase 14
3.7. Withdrawals of initial marketing authorisation application 14

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 14
4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion 14
4.1.1. Biktarvy - bictegravir / emtricitabine / tenofovir alafenamide - EMEA/H/C/004449/X/0040/G14
4.1.2. Genvoya - elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide - EMEA/H/C/004042/X/0079/G 15
4.1.3. Zejula - niraparib - Orphan - EMEA/H/C/004249/X/0029 15
4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues 15
4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question 15
4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008 15
4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 16

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008 16
5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information 16
5.1.1. Adtralza - tralokinumab - EMEA/H/C/005255/II/0002 16

5.1.2. Cabometyx - cabozantinib - EMEA/H/C/004163/II/0023 16
5.1.3. Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/II/0014 16
5.1.4. Gavreto - pralsetinib - EMEA/H/C/005413/II/0002/G 17
5.1.5. Imbruvica - ibrutinib - EMEA/H/C/003791/II/0070 17
5.1.6. Jakavi - ruxolitinib - EMEA/H/C/002464/II/0053 17
5.1.7. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0117 18
5.1.8. Kymriah - tisagenlecleucel - Orphan - ATMP - EMEA/H/C/004090/II/0044 18
5.1.9. Nexpovio - selinexor - EMEA/H/C/005127/II/0001/G 19
5.1.10. Polivy - polatuzumab vedotin - Orphan - EMEA/H/C/004870/II/0012 19
5.1.11. Tecartus - autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured - Orphan - ATMP - EMEA/H/C/005102/II/0008/G 19
5.1.12. Tecentriq - atezolizumab - EMEA/H/C/004143/II/0064 20
5.1.13. Ultomiris - ravulizumab - EMEA/H/C/004954/II/0026 20
5.1.14. Vyxeos liposomal - daunorubicin / cytarabine - Orphan - EMEA/H/C/004282/II/0018/G 20
5.1.15. WS2150 DuoPlavin - clopidogrel / acetylsalicylic acid - EMEA/H/C/001143/WS2150/0060 Iscover - clopidogrel - EMEA/H/C/000175/WS2150/0146 Plavix - clopidogrel - EMEA/H/C/000174/WS2150/0145 21
5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 21
5.2.1. Olumiant - baricitinib - EMEA/H/C/004085/II/0028 21
5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 22
6. Medical devices 22
6.1. Ancillary medicinal substances - initial consultation 22
6.2. Ancillary medicinal substances – post-consultation update 22
6.3. Companion diagnostics – initial consultation 22
6.3.1. in vitro diagnostic medical device - EMEA/H/D/006065 22
6.4. Companion diagnostics – follow-up consultation 22
7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use) 22
7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use) 22
8. Pre-submission issues 23
8.1. Pre-submission issue 23
8.1.1. Glofitamab - Orphan - H0005751 23
8.2. Priority Medicines (PRIME) 23
8.2.1. List of applications received 23
8.2.2. Recommendation for PRIME eligibility 23

9. Post-authorisation issues 23

9.1. Post-authorisation issues 23

9.1.1. Defitelio - defibrotide – Orphan - EMEA/H/C/002393/II/0056 23

9.1.2. Raxone - idebenone – Orphan - EMEA/H/C/003834/II/0031 24

9.1.3. Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/II/005624

9.1.4. Veklury - remdesivir - EMEA/H/C/005622/R/0031 24

9.1.5. Blenrep - belantamab mafodotin - EMEA/H/C/PSUSA/00010869/202108 24

9.1.6. Piqray - alpelisib - EMEA/H/C/004804/II/0008/G 25

9.1.7. Rubraca - rucaparib - EMEA/H/C/004272/II/0029 25

9.1.8. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0115 25

10. Referral procedures 26

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004 26

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004 . 26

10.2.1. Presence of nitrosamine impurities in human medicinal products containing chemically synthesised active pharmaceutical ingredients EMEA/H/A-5(3)/1490 26

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004 26

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC 26

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC 26

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC 26

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC 27

10.8. Procedure under Article 107(2) of Directive 2001/83/EC 27

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003 27

10.10. Procedure under Article 29 of Regulation (EC) 1901/2006 27

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008 27

11. Pharmacovigilance issue 27

11.1. Early Notification System 27

12. Inspections 27

12.1. GMP inspections 27

12.2. GCP inspections 27

12.3. Pharmacovigilance inspections 28

12.4. GLP inspections 28

13. Innovation Task Force 28

13.1. Minutes of Innovation Task Force 28

13.2. Innovation Task Force briefing meetings 28

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004 28

13.4. Nanomedicines activities 28

14. Organisational, regulatory and methodological matters 28

14.1. Mandate and organisation of the CHMP 28

14.1.1. CHMP Co-rapporteur critique 28

14.2. Coordination with EMA Scientific Committees 28

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC) 28

14.2.2. Paediatric Committee (PDCO) 29

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups 29

14.3.1. Biologics Working Party (BWP) 29

14.3.2. Scientific Advice Working Party (SAWP) 29

14.3.3. Ad-hoc Influenza Working Group 29

14.3.4. Oncology Working Party (ONCWP) 30

14.3.5. Recommendation for the membership of Working Parties 30

14.3.6. Appointment of the chair and vice-chair of the Oncology Scientific Advice Group 30

14.4. Cooperation within the EU regulatory network 30

14.5. Cooperation with International Regulators 30

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee 30

14.7. CHMP work plan 30

14.8. Planning and reporting 31

14.8.1. Update of the Business Pipeline report for the human scientific committees 31

14.9. Others 31

14.9.1. Pharma Strategy 31

15. Any other business 31

15.1. AOB topic 31

15.1.1. Update on COVID-19 31

15.1.2. Diabetes guideline 31

Explanatory notes 32

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session to be held 21-24 March 2022. See March 2022 CHMP minutes (to be published post April 2022 CHMP meeting).

1.2. Adoption of agenda

CHMP agenda for 21-24 March 2022.

1.3. Adoption of the minutes

CHMP minutes for 21-14 February 2022.

Minutes from PReparatory and Organisational Matters (PROM) meeting held on 14 March 2022.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. betulae cortex dry extract (5-10: 1); extraction solvent: n-heptane 95% (w/w) - Orphan - EMEA/H/C/005035

Amryt Pharmaceuticals DAC; Treatment to achieve accelerated healing of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients from birth onwards.

Scope: Oral explanation

Action: Oral explanation to be held on 22 March 2022 at 14:00

List of Outstanding Issues adopted on 27.01.2022, 11.11.2021. List of Questions adopted on 22.07.2021.

2.1.2. budesonide, micronised - Orphan - EMEA/H/C/005653

Calliditas Therapeutics AB; treatment of primary immunoglobulin A (IgA) nephropathy

Scope: Possible oral explanation

Action: Oral explanation to be held on 23 March 2022 at 11:00

List of Outstanding Issues adopted on 27.01.2022. List of Questions adopted on 14.09.2021.

2.1.3. capmatinib - EMEA/H/C/004845

treatment of non-small cell lung cancer (NSCLC)

Scope: Oral explanation

Action: Oral explanation to be held on 23 March 2022 at 15:30

List of Outstanding Issues adopted on 27.01.2022. List of Questions adopted on 16.09.2021.

2.2. Re-examination procedure oral explanations

No items

2.3. Post-authorisation procedure oral explanations

2.3.1. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0109

Merck Sharp & Dohme B.V.

Rapporteur: Armando Genazzani, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication for Keytruda as monotherapy in the treatment of unresectable or metastatic MSI-H or dMMR colorectal, endometrial, gastric, small intestine, biliary, or pancreatic cancer in adults who have received prior therapy. The proposed indication is based on the results from the KEYNOTE-164 (KN164) and KEYNOTE-158 (KN158) trials.
As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. An updated version of the RMP (Version 34.1) has been submitted."

Scope: Oral explanation

Action: Oral explanation to be held on 22 March 2022 at 16:00

Request for Supplementary Information adopted on 24.02.2022, 14.10.2021.

2.4. Referral procedure oral explanations

No items

3. Initial applications

3.1. Initial applications; Opinions

3.1.1. amifampridine - EMEA/H/C/005839

treatment of Lambert-Eaton Myasthenic Syndrome

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 27.01.2022. List of Questions adopted on 16.09.2021.

3.1.2. leuprorelin - EMEA/H/C/005034

indicated for the treatment of hormone dependent advanced prostate cancer

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 27.01.2022. List of Questions adopted on 23.07.2020.

3.1.3. ciltacabtagene autoleucel - PRIME - Orphan - ATMP - EMEA/H/C/005095

Janssen-Cilag International NV; treatment of multiple myeloma

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 10.12.2021. List of Questions adopted on 10.09.2021.

3.1.4. tixagevimab / cilgavimab - EMEA/H/C/005788

prophylaxis of COVID-19 in adults 18 years of age and older

Scope: Opinion

Action: For adoption

3.1.5. arimoclomol - Orphan - EMEA/H/C/005203

Orphazyme A/S; treatment of Niemann-Pick disease type C (NPC)

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 16.09.2021. List of Questions adopted on 25.03.2021.

3.1.6. doxorubicin - EMEA/H/C/005320

treatment of breast cancer, ovarian cancer, progressive multiple myeloma and AIDS-related Kaposi's sarcoma

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 27.01.2022, 26.03.2020. List of Questions adopted on 17.10.2019.

3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

3.2.1. doxorubicin hydrochloride - EMEA/H/C/005330

treatment of breast cancer, treatment of ovarian cancer, treatment of multiple myeloma, treatment of AIDS related Kaposi's sarcoma

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 28.05.2020.

3.2.2. ertapenem - EMEA/H/C/005815

treatment of bacterial infections and prophylaxis of surgical site infection following elective colorectal surgery

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 24.06.2021.

3.2.3. ganirelix - EMEA/H/C/005641

Prevention of premature luteinising hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproduction techniques (ART).

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 22.07.2021.

3.2.4. mosunetuzumab - Orphan - EMEA/H/C/005680

Accelerated assessment

Roche Registration GmbH; refractory follicular lymphoma (FL)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 25.01.2022.

3.2.5. melphalan flufenamide - Orphan - EMEA/H/C/005681

Oncopeptides AB; treatment of multiple myeloma

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 16.09.2021.

3.2.6. mitapivat - Orphan - EMEA/H/C/005540

Agios Netherlands B.V.; treatment of pyruvate kinase deficiency

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 11.11.2021.

3.2.7. valoctocogene roxaparvovec - Orphan - ATMP - EMEA/H/C/005830

Accelerated assessment

BioMarin International Limited; treatment of severe haemophilia A

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 05.11.2021.

3.2.8. eptacog beta (activated) - EMEA/H/C/005655

treatment and for the prevention of bleeding

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 24.06.2021.

3.2.9. sitagliptin / metformin hydrochloride - EMEA/H/C/005850

treatment of type 2 diabetes mellitus

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 16.09.2021.

3.2.10. sugammadex - EMEA/H/C/005760

Reversal of neuromuscular blockade induced by rocuronium or vecuronium

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 22.07.2021.

3.2.11. tezepelumab - EMEA/H/C/005588

add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 14.10.2021.

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

3.3.1. tabelecleucel - PRIME - Orphan - ATMP - EMEA/H/C/004577

Accelerated assessment

Atara Biotherapeutics Ireland Limited; treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV^+ PTLD)

Scope: List of questions

Action: For information

3.3.2. abaloparatide - EMEA/H/C/005928

treatment of osteoporosis

Scope: List of questions

Action: For adoption

3.3.3. spironolactone ph. eur. - EMEA/H/C/005535

Management of refractory oedema

Scope: List of questions

Action: For adoption

3.3.4. miglustat - Orphan - EMEA/H/C/005695

Amicus Therapeutics Europe Limited; treatment of adults aged 18 years and older with a confirmed diagnosis of Pompe disease

Scope: List of questions

Action: For adoption

3.3.5. pirfenidone - EMEA/H/C/005862

treatment of Idiopathic Pulmonary Fibrosis (IPF)

Scope: List of questions

Action: For adoption

3.3.6. cipaglucosidase alfa - Orphan - EMEA/H/C/005703

Amicus Therapeutics Europe Limited; treatment of adults aged 18 years and older with a confirmed diagnosis of Pompe disease

Scope: List of questions

Action: For adoption

3.3.7. sugammadex - EMEA/H/C/005935

reversal of neuromuscular blockade induced by rocuronium or vecuronium

Scope: List of questions

Action: For adoption

3.3.8. infigratinib - Orphan - EMEA/H/C/005361

Helsinn Birex Pharmaceuticals Limited; treatment of cholangiocarcinoma

Scope: List of questions

Action: For adoption

3.3.9. vadadustat - EMEA/H/C/005131

Treatment of anaemia

Scope: List of questions

Action: For adoption

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. dengue tetravalent vaccine (live, attenuated) - Article 58 - EMEA/H/W/005362

prevention of dengue disease

Scope: Letter from the applicant dated 09 March 2022 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in November 2021.

Action: For adoption

List of Outstanding Issues adopted on 11.11.2021. List of Questions adopted on 24.06.2021.

3.4.2. dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/005155

prevention of dengue disease

Scope: Letter from the applicant dated 09 March 2022 requesting an extension to the clock

stop to respond to the list of outstanding issues adopted in November 2021.

Action: For adoption

List of Outstanding Issues adopted on 11.11.2021. List of Questions adopted on 24.06.2021.

3.4.3. iodine (131I) omburtamab - Orphan - EMEA/H/C/005499

Y-Mabs Therapeutics A/S treatment of neuroblastoma

Scope: Letter from the applicant dated 08 March 2022 requesting an extension to the clock stop to respond to the list of questions adopted in September 2021. The request was adopted by CHMP via written procedure on 10 March 2022.

Action: For information

List of Questions adopted on 16.09.2021.

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

No items

3.6. Initial applications in the decision-making phase

No items

3.7. Withdrawals of initial marketing authorisation application

No items

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Biktarvy - bictegravir / emtricitabine / tenofovir alafenamide - EMEA/H/C/004449/X/0040/G

Gilead Sciences Ireland UC

Rapporteur: Jean-Michel Race, Co-Rapporteur: Bruno Sepodes, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Extension application to introduce a new strength 30 mg/120 mg/15 mg. The extension application is grouped with a type II variation (C.I.6.a) to include a paediatric indication: use in patients 2 years of age and older and weighing at least 14 kg. Sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated to support the

extended indication. The RMP (version 3.1) is updated in accordance."

Action: For adoption

List of Questions adopted on 14.10.2021.

4.1.2. Genvoya - elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide - EMEA/H/C/004042/X/0079/G

Gilead Sciences Ireland UC

Rapporteur: Bruno Sepodes, PRAC Rapporteur: Ilaria Baldelli

Scope: "Extension application to introduce a new strength (90 mg/90 mg/120 mg/6 mg film-coated tablets). The extension application is grouped with a type II variation (C.I.6.a) to include treatment of human immunodeficiency virus 1 (HIV 1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir in paediatric patients aged from 2 years and with body weight at least 14 kg. Sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated to support the extended indication. The RMP (version 5.1) is updated in accordance."

Action: For adoption

List of Questions adopted on 11.11.2021.

4.1.3. Zejula - niraparib - Orphan - EMEA/H/C/004249/X/0029

GlaxoSmithKline (Ireland) Limited

Rapporteur: Ingrid Wang, PRAC Rapporteur: Jan Neuhauser

Scope: "Extension application to introduce a new pharmaceutical form (100 mg film-coated tablet). The RMP (version 5.1) is updated in accordance."

Action: For adoption

List of Outstanding Issues adopted on 16.12.2021. List of Questions adopted on 14.10.2021.

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

No items

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

No items

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

No items

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Adtralza - tralokinumab - EMEA/H/C/005255/II/0002

LEO Pharma A/S

Rapporteur: Jayne Crowe, PRAC Rapporteur: Kimmo Jaakkola

Scope: "Extension of indication to include treatment of adolescent patients (12-17 years) for Adtralza based on final study LP0162-1334 (ECZTRA 6): a multicentre, randomised, double-blind, placebo-controlled study in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis to evaluate the efficacy and safety of tralokinumab monotherapy in this population group. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance."

Action: For adoption

5.1.2. Cabometyx - cabozantinib - EMEA/H/C/004163/II/0023

Ipsen Pharma

Rapporteur: Ingrid Wang, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include monotherapy treatment of adults and adolescent patients aged 12 years and older, with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy for Cabometyx; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 6.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 24.02.2022, 11.11.2021.

5.1.3. Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/II/0014

Daiichi Sankyo Europe GmbH

Rapporteur: Thalia Marie Estrup Blicher, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension of indication for Enhertu to include treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.2 of the RMP has also been submitted.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

5.1.4. Gavreto - pralsetinib - EMEA/H/C/005413/II/0002/G

Roche Registration GmbH

Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Annika Folin

Scope: "Extension of indication to include monotherapy treatment of adult and paediatric patients 12 years of age and older with locally advanced or metastatic RET-mutant medullary thyroid cancer for Gavreto; based on the efficacy and safety data obtained from the pivotal study BO42863 (ARROW). As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted. Furthermore, some minor changes to the PI have been implemented in line with the latest Anticancer Guidelines Recommendations. Extension of indication to include monotherapy treatment of adult and paediatric patients 12 years of age and older with locally advanced or metastatic RET fusion-positive thyroid cancer for Gavreto; based on the efficacy and safety data obtained from the pivotal study BO42863 (ARROW). As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

5.1.5. Imbruvica - ibrutinib - EMEA/H/C/003791/II/0070

Janssen-Cilag International N.V.

Rapporteur: Filip Josephson, Co-Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "Extension of the existing CLL indication to include combination treatment with venetoclax for previously untreated patients based on efficacy and safety data from phase 3 study GLOW and phase 2 study CAPTIVATE. The SmPC is revised to reflect the information on the combination with venetoclax. The PL is updated accordingly. The RMP version 18.4 has been submitted. Justification to support one-year extension of the marketing protection period is included in the submission.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

5.1.6. Jakavi - ruxolitinib - EMEA/H/C/002464/II/0053

Novartis Europharm Limited

Rapporteur: Filip Josephson, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Annika Folin

Scope: "Extension of indication to include treatment of patients with GvHD aged 12 years and older who have inadequate response to corticosteroids or other systemic therapies for Jakavi; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 13.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives for The Netherlands in the Package Leaflet."

Action: For adoption

Request for Supplementary Information adopted on 16.12.2021, 24.06.2021.

5.1.7. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0117

Merck Sharp & Dohme B.V.

Rapporteur: Armando Genazzani, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include a new indication for Keytruda, in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic cervical cancer in adults; as a consequence, sections 4.1 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 38.1 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 27.01.2022.

5.1.8. Kymriah - tisagenlecleucel - Orphan - ATMP - EMEA/H/C/004090/II/0044

Novartis Europharm Limited

Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include treatment of adult patients with follicular lymphoma (FL) after two or more lines of therapy who are refractory or relapsed during or within 6 months after completion of anti-CD20 antibody maintenance or relapsed after autologous haematopoietic stem cell transplantation (HSCT) for Kymriah. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC and corresponding sections in the Package Leaflet are updated accordingly. The RMP has been updated to version 4.0 to align with the indication extension. Lastly, the minor editorial corrections are made throughout the SmPC and package leaflet to align with the current QRD template version 10.2.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 10.12.2021.

5.1.9. Nexpovio - selinexor - EMEA/H/C/005127/II/0001/G

Karyopharm Europe GmbH

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Menno van der Elst

Scope: "Group of variations including an extension of indication for Nexpovio in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy and a quality variation for the addition of a new pack size to align with the dose modification guidance for the new indication. Sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 6.5 of the SmPC are updated to reflect the new indication and the new pack size. Annex II is updated to reflect the completion of the Specific Obligation. The Labelling and Package Leaflet are amended accordingly. The RMP (v 1.1) is amended consequently."

Action: For adoption

Request for Supplementary Information adopted on 16.12.2021, 22.07.2021.

5.1.10. Polivy - polatuzumab vedotin - Orphan - EMEA/H/C/004870/II/0012

Roche Registration GmbH

Rapporteur: Alexandre Moreau, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Annika Folin

Scope: "Extension of the indication to include: Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone, is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL) based on the efficacy and safety data from the Pivotal Phase III study GO39942 (POLARIX). This submission fulfils SOB003 thus supporting the switch from CMA to full MA. Annexes I, II, IIIB are revised. The RMP is also updated."

Action: For adoption

Request for Supplementary Information adopted on 24.02.2022.

5.1.11. Tecartus - autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured - Orphan - ATMP - EMEA/H/C/005102/II/0008/G

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Group of variations including an extension of indication to include treatment of adult patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukaemia (B-ALL) for Tecartus and a type IB variation. As a consequence, sections 2.2, 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 1.1 of the RMP has also been submitted. Furthermore, the PI is brought in line with the latest QRD template." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 10.09.2021.

5.1.12. Tecentriq - atezolizumab - EMEA/H/C/004143/II/0064

Roche Registration GmbH

Rapporteur: Thalia Marie Estrup Blicher, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "C.I.6 (Extension of indication)
Extension of indication to include adjuvant treatment of non-small cell lung cancer (NSCLC) following resection and platinum-based chemotherapy for adult patients whose tumours have PD-L1 expression on ≥ 1% of tumour cells (TC) for Tecentriq as monotherapy based on the results from the pivotal phase III study GO29527 (IMpower010); as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of both the Tecentriq 840 mg concentrate for solution for infusion SmPC and the Tecentriq 1,200 mg concentrate for solution for infusion SmPC are updated. Minor editorial changes have been made throughout the SmPC. The Package Leaflets are updated in accordance. Version 21.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 14.10.2021.

5.1.13. Ultomiris - ravulizumab - EMEA/H/C/004954/II/0026

Alexion Europe SAS

Rapporteur: Blanca Garcia-Ochoa, Co-Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Kimmo Jaakkola

Scope: "Extension of indication to include treatment of adult patients with generalised myasthenia gravis (gMG). As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 and 6.6 of the SmPC and corresponding sections in the Package Leaflet are updated accordingly. The RMP has been updated to version 4.0 to align with the indication extension. Lastly, the minor editorial corrections are made throughout the SmPC and package leaflet. The Applicant also requested 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)."

Action: For adoption

5.1.14. Vyxeos liposomal - daunorubicin / cytarabine - Orphan - EMEA/H/C/004282/II/0018/G

Jazz Pharmaceuticals Ireland Limited

Rapporteur: Johanna Lähteenvuo, Co-Rapporteur: Janet Koenig, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension of indication to add treatment of relapsed/refractory AML in paediatric patients with subsequent updates to sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC based on the new safety and efficacy data from the paediatric clinical study AAML1421. The package leaflet is updated accordingly. The RMP version 1.1 has also been submitted. In addition, the PI is updated in line with the latest QRD template 10.2.
Submission of the final data from paediatric clinical study CPX-MA-1201 in support of the

extension of indication." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 11.11.2021, 20.05.2021.

5.1.15. WS2150
DuoPlavin - clopidogrel / acetylsalicylic acid - EMEA/H/C/001143/WS2150/0060
Iscover - clopidogrel - EMEA/H/C/000175/WS2150/0146
Plavix - clopidogrel - EMEA/H/C/000174/WS2150/0145

sanofi-aventis groupe

Lead Rapporteur: Bruno Sepodes, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension of indication to include clopidogrel in combination with acetylsalicylic acid in ST segment elevation acute myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI); as a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. Version 1.5 of the RMP has also been submitted. In addition, an editorial update has been made to the labelling."

Action: For adoption

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

5.2.1. Olumiant - baricitinib - EMEA/H/C/004085/II/0028

Eli Lilly Nederland B.V.

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Christophe Focke, PRAC Rapporteur: Adam Przybylkowski

Scope: "C.I.6 - Extension of indication to include treatment of coronavirus disease 2019 (COVID 19) in hospitalised adult and paediatric patients aged 10 years and older who require low-flow oxygen or non-invasive ventilation/high flow oxygen for Olumiant; as a consequence, sections 4.1, 4.2, 4.4, 4.6, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Annex II and the Package Leaflet are updated in accordance. Version 11.1 of the RMP has also been submitted.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Letter from the applicant dated 07 March 2022 requesting an extension to the clock stop to respond to the request of supplementary information adopted in October 2021. The request was adopted by CHMP via written procedure on 11 March 2022.

Action: For information

Request for Supplementary Information adopted on 14.10.2021, 22.07.2021.

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

6. Medical devices

6.1. Ancillary medicinal substances - initial consultation

No items

6.2. Ancillary medicinal substances – post-consultation update

No items

6.3. Companion diagnostics – initial consultation

6.3.1. in vitro diagnostic medical device - EMEA/H/D/006065

In vitro quantitative determination of anti-Müllerian hormone (AMH) in human serum and plasma

Scope: Opinion

Action: For adoption

6.4. Companion diagnostics – follow-up consultation

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

8.1.1. Glofitamab - Orphan - H0005751

Roche Registration GmbH; indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphomas (DLBCL), high grade B cell lymphoma (HGBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

8.2. Priority Medicines (PRIME)

Information related to priority medicines cannot be released at present time as these contain commercially confidential information

8.2.1. List of applications received

Action: For information

8.2.2. Recommendation for PRIME eligibility

Action: For adoption

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Defitelio - defibrotide – Orphan - EMEA/H/C/002393/II/0056

Gentium S.r.l.

Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Submission of the final report from study 15-007 listed as a specific obligation in the Annex II of the Product Information. This is a phase 3, randomised, adaptive study (15-007) of Defibrotide vs. best supportive care in the prevention of hepatic venoocclusive disease in adult and paediatric patients undergoing hematopoietic stem cell transplant (HSCT). The RMP version 9 has also been submitted.
The MAH has also taken the opportunity to align the PI to the latest QRD template 10.2 which replaces the United Kingdom with United Kingdom (Northern Ireland) in the PIL.

In addition, the MAH is correcting the following errata during the linguistic review of the PI: correction of the paragraph number for Regulation (EC) No 726.2004 which was cited incorrectly in Annex II of the French PI and formatting updates to Norwegian and Swedish language PIs."

Action: For adoption

Request for Supplementary Information adopted on 10.03.2022, 28.10.2021, 08.07.2021.

9.1.2. Raxone - idebenone – Orphan - EMEA/H/C/003834/II/0031

Santhera Pharmaceuticals (Deutschland) GmbH

Rapporteur: John Joseph Borg, PRAC Rapporteur: Amelia Cupelli

Scope: "Update of sections 4.2, 4.4, 4.9 and 5.1 of the SmPC based on the final study report from the PAROS study SNT-IV-003 (SOB003; listed as a cat 2 study in the RMP): "A non-interventional study of clinical experience in patients prescribed Raxone for the treatment of Leber's Hereditary Optic Neuropathy (LHON)". Annex II is updated in accordance. A revised RMP version 1.14 was also submitted."

Action: For adoption

9.1.3. Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/II/0056

Orexigen Therapeutics Ireland Limited

Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber

Scope: "Submission of updated study design and protocol synopsis for CVOT-2 study, a category 1 study listed in Annex II.D (ANX/001.7) undertaken to assess the effect of naltrexone extended release (ER) / bupropion ER on the occurrence of major adverse cardiovascular events (MACE), as requested in the CHMP AR for ANX/001.6. The Annex II and the RMP version 13 are updated accordingly."

Action: For adoption

9.1.4. Veklury - remdesivir - EMEA/H/C/005622/R/0031

Gilead Sciences Ireland UC

Rapporteur: Janet Koenig, PRAC Rapporteur: Eva Jirsová

Scope: Renewal of conditional marketing authorisation

Action: For adoption

9.1.5. Blenrep - belantamab mafodotin - EMEA/H/C/PSUSA/00010869/202108

GlaxoSmithKline (Ireland) Limited

Rapporteur: Johanna Lähteenvuo, PRAC Rapporteur: Annika Folin

Scope: To update sections 4.4 of the SmPC in view of available data from spontaneous

reports and in view of a non-clinical signal and plausible mechanism of action, which suggest a causal relationship between belantamab mafodotin and pneumonitis and also section 4.8 to add 'pneumonitis' as an ADR. The PL is updated accordingly.

Action: For adoption

9.1.6. Piqray - alpelisib - EMEA/H/C/004804/II/0008/G

Novartis Europharm Limited

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Menno van der Elst

Scope: "Update of section 5.1 of the SmPC based on final results from study CBYL719C2301 (SOLAR-1) listed as a PAES in the Annex II; this is a phase III, randomized, double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment; the Annex II is updated accordingly. In addition, the MAH is updating the ATC code in the SmPC. The RMP version 5.0 has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 28.10.2021.

9.1.7. Rubraca - rucaparib - EMEA/H/C/004272/II/0029

Clovis Oncology Ireland Limited

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Annika Folin

Scope: "Update of sections 4.4, 4.8 and 5.1 of the SmPC based on final results from study CO-338-043 (ARIEL4); this is a phase 3, multicentre, open-label, randomised study evaluating the efficacy and safety of rucaparib versus chemotherapy for treatment of relapsed ovarian cancer listed as a specific obligation in the Annex II; the Package Leaflet is updated accordingly. The RMP version 6.1 has also been submitted. With this variation application, the MAH requests for the Rubraca marketing authorisation to no longer be subject to specific obligations. The SmPC, Annex II and PL are updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes and bring the PI in line with the latest QRD template version 10.2 Rev.1."

Action: For adoption

Request for Supplementary Information adopted on 11.11.2021.

9.1.8. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0115

Merck Sharp & Dohme B.V.

Rapporteur: Armando Genazzani

Scope: "Update of section 5.1 of the SmPC in order to update efficacy information based on final results from study KEYNOTE-426 listed as imposed PAES in the Annex II; this is a Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in combination with Axitinib versus Sunitinib Monotherapy as a First-line

Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC)."

Action: For adoption

Request for Supplementary Information adopted on 02.12.2021.

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

No items

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

10.2.1. Presence of nitrosamine impurities in human medicinal products containing chemically synthesised active pharmaceutical ingredients EMEA/H/A-5(3)/1490

MAHs: various

Referral Rapporteur: Martina Weise, Referral Co-Rapporteur: Kristina Dunder

Scope: Update on implementation of Article 5(3)

Action: For information

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

No items

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

No items

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

No items

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

No items

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

No items

11. Pharmacovigilance issue

11.1. Early Notification System

March 2022 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

No items

13.2. Innovation Task Force briefing meetings

No items

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

14.1.1. CHMP Co-rapporteur critique

Experience of the implementation of Co-Rapporteur critique in initial marketing authorisation applications. Follow-up on the February PROM meeting.

Action: For information

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

Summary of recommendations and advice of PRAC meeting held on 07-10 March 2022

Action: For information

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for March 2022

Action: For adoption

14.2.2. Paediatric Committee (PDCO)

PIPs reaching D30 at March 2022 PDCO

Action: For information

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Biologics Working Party (BWP)

Chair: Sol Ruiz

Reports from BWP March 2022 meeting to CHMP for adoption:

- 16 reports on products in scientific advice and protocol assistance
- 8 reports on products in pre-authorisation procedures
- 3 reports on products in post-authorisation procedures
- 2 reports on products in plasma master file

Action: For adoption

14.3.2. Scientific Advice Working Party (SAWP)

Chair: Paolo Foggi

Report from the SAWP meeting held on 07-10 March 2022. Table of conclusions

Action: For information

Scientific advice letters:

Information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

14.3.3. Ad-hoc Influenza Working Group

Scope: EU Strain selection for the Influenza Vaccines for the Season 2022/2023: Report from the Ad Hoc Influenza working group to the BWP

Action: For adoption

Scope: EU Recommendation for the Seasonal Influenza Vaccine Composition for the Season 2022/2023

Action: For adoption

14.3.4. Oncology Working Party (ONCWP)

Scope: Nomination of Chair, Vice-Chair and new member following the resignation of Sinan B. Sarac.

Action: For adoption

14.3.5. Recommendation for the membership of Working Parties

Confirmation of membership of the following working parties:

Central Nervous System WP
Cardiovascular WP
Rheumatology and Immunology WP
Vaccine WP
Infectious Diseases WP
Haematology WP
Methodology WP
Non-clinical WP
J3Rs WP

Action: For adoption

14.3.6. Appointment of the chair and vice-chair of the Oncology Scientific Advice Group

Formal appointment of the chair and vice-chair of the SAG Oncology following the elections.

Action: For endorsement

14.4. Cooperation within the EU regulatory network

No items

14.5. Cooperation with International Regulators

No items

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

14.7. CHMP work plan

No items

14.8. Planning and reporting

14.8.1. Update of the Business Pipeline report for the human scientific committees

2022 initial marketing authorisation application submissions with eligibility request to central procedure

Action: For information

14.9. Others

14.9.1. Pharma Strategy

Revision of the Pharmaceutical legislation: update

Action: For discussion

15. Any other business

15.1. AOB topic

15.1.1. Update on COVID-19

Action: For information

15.1.2. Diabetes guideline

Update on revision of the diabetes guideline following the meeting of the drafting group

Action: For discussion

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 2)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications *(section 3)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths,

formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a

particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 11)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 12)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 13)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 14.3.1)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 14.2)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 14.3)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

24 March 2022
EMA/CHMP/126032/2022

Annex to 21-24 March 2022 CHMP Agenda

Pre-submission and post-authorisations issues

A. PRE-SUBMISSION ISSUES 3
A.1. ELIGIBILITY REQUESTS 3
A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications 3
A.3. PRE-SUBMISSION ISSUES FOR INFORMATION 3

B. POST-AUTHORISATION PROCEDURES OUTCOMES 3
B.1. Annual re-assessment outcomes 3
B.1.1. Annual reassessment for products authorised under exceptional circumstances 3
B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES 4
B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal 4
B.2.2. Renewals of Marketing Authorisations for unlimited validity 4
B.2.3. Renewals of Conditional Marketing Authorisations 5
B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES 6
B.4. EPARs / WPARs 8
B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES 10
B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects 10
B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects 17
B.5.3. CHMP-PRAC assessed procedures 24
B.5.4. PRAC assessed procedures 34
B.5.5. CHMP-CAT assessed procedures 42
B.5.6. CHMP-PRAC-CAT assessed procedures 43
B.5.7. PRAC assessed ATMP procedures 43
B.5.8. Unclassified procedures and work-sharing procedures of type I variations 43
B.5.9. Information on withdrawn type II variation / WS procedure 44
B.5.10. Information on type II variation / WS procedure with revised timetable 45
B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION 45
B.6.1. Start of procedure for New Applications: timetables for information 45
B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information 46

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information 46
B.6.4. Annual Re-assessments: timetables for adoption 47
B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed 48
B.6.6. VARIATIONS – START OF THE PROCEDURE 48
B.6.7. Type II Variations scope of the Variations: Extension of indication 48
B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects 49
B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects 51
B.6.10. CHMP-PRAC assessed procedures 57
B.6.11. PRAC assessed procedures 57
B.6.12. CHMP-CAT assessed procedures 58
B.6.13. CHMP-PRAC-CAT assessed procedures 59
B.6.14. PRAC assessed ATMP procedures 59
B.6.15. Unclassified procedures and worksharing procedures of type I variations 59
B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY 61
B.7.1. Yearly Line listing for Type I and II variations 61
B.7.2. Monthly Line listing for Type I variations 61
B.7.3. Opinion on Marketing Authorisation transfer (MMD only) 61
B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only) 61
B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only) 61
B.7.6. Notifications of Type I Variations (MMD only) 61

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled) 61

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed) 61

E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES 61
E.1. Timetables – starting & ongoing procedures: For information 61

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver 61

G. ANNEX G 61
G.1. Final Scientific Advice (Reports and Scientific Advice letters): 61
G.2. PRIME 61
G.2.1. List of procedures concluding at 21-24 March 2022 CHMP plenary: 62
G.2.2. List of procedures starting in March 2022 for April 2022 CHMP adoption of outcomes 62

H. ANNEX H - Product Shared Mailboxes – e-mail address 62

A. PRE-SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for March 2022: **For adoption**

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for March 2022: **For adoption**

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

Myalepta - metreleptin - EMEA/H/C/004218/S/0023, Orphan
Amryt Pharmaceuticals DAC, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Adam Przybylkowski
Request for Supplementary Information adopted on 27.01.2022.

Orphacol - cholic acid - EMEA/H/C/001250/S/0042, Orphan
Laboratoires CTRS, Rapporteur: Anastasia Mountaki, PRAC Rapporteur: Sofia Trantza

Raxone - idebenone - EMEA/H/C/003834/S/0029, Orphan
Santhera Pharmaceuticals (Deutschland) GmbH, Rapporteur: John Joseph Borg, PRAC Rapporteur: Amelia Cupelli
Request for Supplementary Information adopted on 27.01.2022.

Vyndaqel - tafamidis - EMEA/H/C/002294/S/0076, Orphan
Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Tiphaine Vaillant
Request for Supplementary Information adopted on 24.02.2022.

B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

B.2.2. Renewals of Marketing Authorisations for unlimited validity

Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan - efavirenz / emtricitabine / tenofovir disoproxil - EMEA/H/C/004240/R/0019
Mylan Pharmaceuticals Limited, Generic, Generic of Atripla (SRD), Rapporteur: Bruno Sepodes, PRAC Rapporteur: Martin Huber

Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva - efavirenz / emtricitabine / tenofovir disoproxil - EMEA/H/C/004250/R/0025
Zentiva k.s., Generic, Generic of Atripla (SRD), Rapporteur: Tomas Radimersky, PRAC Rapporteur: Martin Huber
Request for Supplementary Information adopted on 27.01.2022.

Fotivda - tivozanib - EMEA/H/C/004131/R/0021
EUSA Pharma (Netherlands) B.V., Rapporteur: Bruno Sepodes, Co-Rapporteur: Romaldas Mačiulaitis, PRAC Rapporteur: Rugile Pilviniene

LUTATHERA - lutetium (177Lu) oxodotreotide - EMEA/H/C/004123/R/0032, Orphan
Advanced Accelerator Applications, Rapporteur: Janet Koenig, Co-Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Adam Przybylkowski

Rydapt - midostaurin - EMEA/H/C/004095/R/0023, Orphan
Novartis Europharm Limited, Rapporteur: Paula Boudewina van Hennik, Co-Rapporteur: Ingrid Wang, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva
Request for Supplementary Information adopted on 24.02.2022.

Symtuza - darunavir / cobicistat / emtricitabine / tenofovir alafenamide - EMEA/H/C/004391/R/0040

Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Ana Sofia Diniz Martins	

B.2.3. Renewals of Conditional Marketing Authorisations

LIBTAYO - cemiplimab - EMEA/H/C/004844/R/0029 Regeneron Ireland Designated Activity Company (DAC), Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Menno van der Elst	
Nexpovio - selinexor - EMEA/H/C/005127/R/0005 Karyopharm Europe GmbH, Rapporteur: Blanca Garcia-Ochoa, Co-Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Menno van der Elst	
Rozlytrek - entrectinib - EMEA/H/C/004936/R/0007 Roche Registration GmbH, Rapporteur: Armando Genazzani, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst	
Veklury - remdesivir - EMEA/H/C/005622/R/0031 Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, PRAC Rapporteur: Eva Jirsová	See 9.1
Zolgensma - onasemnogene abeparvovec - EMEA/H/C/004750/R/0021, Orphan, ATMP Novartis Gene Therapies EU Limited, Rapporteur: Carla Herberts, Co-Rapporteur: Egbert Flory, CHMP Coordinators: Johann Lodewijk Hillege and Jan Mueller-Berghaus, PRAC Rapporteur: Ulla Wändel Liminga Request for Supplementary Information adopted on 18.02.2022.	

B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

Signal detection

PRAC recommendations on signals adopted at the PRAC meeting held on 07-10 March 2022
PRAC:

Signal of vitiligo

Lemtrada – alemtuzumab

Rapporteur: Thalia Marie Estrup Blicher, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Anette Kirstine Stark
PRAC recommendation on a variation
Action: For adoption

Signal of drug interaction with cannabidiol leading to calcineurin inhibitors and mTOR inhibitors serum levels increased and toxicity

Epidyolex, Advagraf, Envarsus, Modigraf, Tacforius, Afinitor, Votubia, Rapamune, Torisel - Cannabidiol, calcineurin inhibitors: ciclosporin; tacrolimus, mammalian target of rapamycin (mTOR) inhibitors: everolimus, sirolimus, temsirolimus
CHMP Rapporteurs: multiple, PRAC Rapporteur: Ronan Grimes
PRAC recommendation on a variation
Action: For adoption

Signal of capillary Leak Syndrome

Spikevax - Elasomeran, COVID-19 mRNA vaccine (nucleoside modified)

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Andrea Laslop, PRAC Rapporteur: Hans Christian Siersted
PRAC recommendation on a variation
Action: For adoption

PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its March 2022 meeting:

EMEA/H/C/PSUSA/00000962/202107
(desloratadine)
CAPS:
Aerius (EMEA/H/C/000313) (desloratadine), Organon N.V., Rapporteur: Christophe Focke
Azomyr (EMEA/H/C/000310) (desloratadine), Organon N.V., Rapporteur: Christophe Focke
Dasselta (EMEA/H/C/002310) (desloratadine), KRKA, d.d., Novo mesto, Rapporteur: Agnes

Gyurasics
Desloratadine Actavis (EMEA/H/C/002435) (desloratadine), Actavis Group PTC ehf, Rapporteur: Agnes Gyurasics
Desloratadine ratiopharm (EMEA/H/C/002404) (desloratadine), ratiopharm GmbH, Rapporteur: Christophe Focke
Desloratadine Teva (EMEA/H/C/002419) (desloratadine), Teva B.V., Rapporteur: Agnes Gyurasics
Neoclarityn (EMEA/H/C/000314) (desloratadine), Organon N.V., Rapporteur: Christophe Focke
NAPS:
NAPs - EU
PRAC Rapporteur: Jean-Michel Dogné, "16/07/2016 To: 15/07/2021"

EMEA/H/C/PSUSA/00000963/202107
(desloratadine / pseudoephedrine)
CAPS:
Aerinaze (EMEA/H/C/000772) (desloratadine / pseudoephedrine sulphate), Organon N.V., Rapporteur: Christophe Focke, PRAC Rapporteur: Jean-Michel Dogné, "15/07/2016 To: 15/07/2021"

EMEA/H/C/PSUSA/00002127/202108
(natalizumab)
CAPS:
Tysabri (EMEA/H/C/000603) (natalizumab), Biogen Netherlands B.V., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, "07/08/2020 To: 07/08/2021"

EMEA/H/C/PSUSA/00010730/202108
(tezacaftor / ivacaftor)
CAPS:
Symkevi (EMEA/H/C/004682) (tezacaftor / ivacaftor), Vertex Pharmaceuticals (Ireland) Limited, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Rhea Fitzgerald, "12/02/2021 To: 12/08/2021"

EMEA/H/C/PSUSA/00010823/202108
(upadacitinib)
CAPS:
RINVOQ (EMEA/H/C/004760) (upadacitinib), AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce, "15/02/2021 To:

15/08/2021”	
EMEA/H/C/PSUSA/00010869/202108 (belantamab mafodotin) CAPS: **Blenrep** (EMEA/H/C/004935) (belantamab mafodotin), GlaxoSmithKline (Ireland) Limited, Rapporteur: Johanna Lähteenvuo, PRAC Rapporteur: Annika Folin, “05/02/2021 To: 04/08/2021”	See 9.1

B.4. EPARs / WPARs

Amversio - betaine anhydrous - EMEA/H/C/005637 SERB SA, treatment of homocystinuria, Generic, Generic of Cystadane, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Dimethyl fumarate Mylan - dimethyl fumarate - EMEA/H/C/005956 Mylan Ireland Limited, treatment of multiple sclerosis, Generic, Generic of TECFIDERA, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Dimethyl fumarate Neuraxpharm - dimethyl fumarate - EMEA/H/C/006039 Laboratorios Lesvi S.L., treatment of multiple sclerosis, Generic, Duplicate, Generic of TECFIDERA, Duplicate of Dimethyl fumarate Polpharma, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Dimethyl fumarate Polpharma - dimethyl fumarate - EMEA/H/C/005955 Zakłady Farmaceutyczne Polpharma S.A., treatment of multiple sclerosis, Generic, Generic of TECFIDERA, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Dimherity - dimethyl fumarate - EMEA/H/C/006042 Sandoz GmbH, treatment of multiple sclerosis, Generic, Duplicate, Generic of TECFIDERA, Duplicate of Dimethyl fumarate Polpharma, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Inpremzia - insulin human (rDNA) - EMEA/H/C/005331 Baxter Holding B.V., treatment of patients with diabetes mellitus who require intravenous	For information only. Comments can be sent to the PL in case necessary.

insulin, Similar biological application (Article 10(4) of Directive No 2001/83/EC)	
IPIQUE - bevacizumab - EMEA/H/C/005433 Rotterdam Biologics B.V., indicated in adults for the treatment of neovascular macular degeneration associated with aging and diabetes., Well-established use application (Article 10a of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Kapruvia - difelikefalin - EMEA/H/C/005612 Vifor Fresenius Medical Care Renal Pharma France, treatment of pruritus, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
KIMMTRAK - tebentafusp - EMEA/H/C/004929, Orphan Immunocore Ireland Limited, treatment of uveal melanoma, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Orgovyx - relugolix - EMEA/H/C/005353 Myovant Sciences Ireland Limited, treatment of adult patients with advanced prostate cancer., New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Padcev - enfortumab vedotin - EMEA/H/C/005392 Astellas Pharma Europe B.V., treatment of locally advanced (LA) or metastatic urothelial cancer (mUC), New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
PreHevbri - hepatitis B surface antigen - EMEA/H/C/005466 VBI Vaccines B.V., indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults., Known active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
QUVIVIQ - daridorexant - EMEA/H/C/005634 Idorsia Pharmaceuticals Deutschland GmbH, treatment of insomnia, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Sitagliptin Accord - sitagliptin - EMEA/H/C/005598 Accord Healthcare S.L.U., treatment of type 2	For information only. Comments can be sent to the PL in case necessary.

diabetes mellitus, Generic, Generic of Januvia, Generic application (Article 10(1) of Directive No 2001/83/EC)	
Truvelog Mix 30 - insulin aspart - EMEA/H/C/005635 sanofi-aventis groupe, treatment of diabetes mellitus, Similar biological application (Article 10(4) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Vydura - rimegepant - EMEA/H/C/005725 Biohaven Pharmaceutical Ireland DAC, management of migraine, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.

B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

ADYNOVI - rurioctocog alfa pegol - EMEA/H/C/004195/II/0030/G Baxalta Innovations GmbH, Rapporteur: Andrea Laslop Opinion adopted on 17.03.2022.	Positive Opinion adopted by consensus on 17.03.2022.
Alymsys - bevacizumab - EMEA/H/C/005286/II/0007/G Mabxience Research SL, Rapporteur: Christian Gartner Request for Supplementary Information adopted on 17.02.2022.	
Apidra - insulin glulisine - EMEA/H/C/000557/II/0088/G Sanofi-Aventis Deutschland GmbH, Rapporteur: Thalia Marie Estrup Blicher Opinion adopted on 10.03.2022. Request for Supplementary Information adopted on 03.02.2022.	Positive Opinion adopted by consensus on 10.03.2022.
Aranesp - darbepoetin alfa - EMEA/H/C/000332/II/0158 Amgen Europe B.V., Rapporteur: Martina Weise Request for Supplementary Information adopted on 13.01.2022.	
Bimzelx - bimekizumab - EMEA/H/C/005316/II/0003/G	

UCB Pharma S.A., Rapporteur: Peter Kiely Request for Supplementary Information adopted on 13.01.2022.	
Bimzelx - bimekizumab - EMEA/H/C/005316/II/0004 UCB Pharma S.A., Rapporteur: Peter Kiely Opinion adopted on 10.03.2022. Request for Supplementary Information adopted on 20.01.2022.	Positive Opinion adopted by consensus on 10.03.2022.
Cerezyme - imiglucerase - EMEA/H/C/000157/II/0123/G Genzyme Europe BV, Rapporteur: Johann Lodewijk Hillege Opinion adopted on 03.03.2022. Request for Supplementary Information adopted on 13.01.2022, 14.10.2021.	Positive Opinion adopted by consensus on 03.03.2022.
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0105 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson	
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0109/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 10.03.2022.	Positive Opinion adopted by consensus on 10.03.2022.
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0112/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson	
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0115/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 03.03.2022.	Positive Opinion adopted by consensus on 03.03.2022.
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0121/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson	
COVID-19 Vaccine Janssen - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein - EMEA/H/C/005737/II/0040 Janssen-Cilag International N.V., Rapporteur: Christophe Focke Opinion adopted on 17.03.2022.	Positive Opinion adopted by consensus on 17.03.2022.
Elaprase - idursulfase - EMEA/H/C/000700/II/0095	

Shire Human Genetic Therapies AB, Rapporteur: Johann Lodewijk Hillege	
Enbrel - etanercept - EMEA/H/C/000262/II/0243/G Pfizer Europe MA EEIG, Rapporteur: Maria Concepcion Prieto Yerro Request for Supplementary Information adopted on 03.02.2022, 02.09.2021.	
Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/II/0010 Daiichi Sankyo Europe GmbH, Rapporteur: Thalia Marie Estrup Blicher Opinion adopted on 03.03.2022. Request for Supplementary Information adopted on 16.12.2021, 28.10.2021.	Positive Opinion adopted by consensus on 03.03.2022.
Erbitux - cetuximab - EMEA/H/C/000558/II/0092 Merck Europe B.V., Rapporteur: Filip Josephson Opinion adopted on 03.03.2022. Request for Supplementary Information adopted on 13.01.2022.	Positive Opinion adopted by consensus on 03.03.2022.
Febuxostat Mylan - febuxostat - EMEA/H/C/004374/II/0012 Mylan Pharmaceuticals Limited, Generic, Generic of Adenuric, Rapporteur: Elita Poplavska Request for Supplementary Information adopted on 27.01.2022.	
Flucelvax Tetra - influenza vaccine surface antigen inactivated prepared in cell cultures - EMEA/H/C/004814/II/0025/G Seqirus Netherlands B.V., Rapporteur: Sol Ruiz	
Fulphila - pegfilgrastim - EMEA/H/C/004915/II/0029 Viatris Limited, Rapporteur: Martina Weise	
Hemlibra - emicizumab - EMEA/H/C/004406/II/0029/G Roche Registration GmbH, Rapporteur: Alexandre Moreau Request for Supplementary Information adopted on 17.03.2022.	Request for supplementary information adopted with a specific timetable.
Hepsera - adefovir dipivoxil - EMEA/H/C/000485/II/0087 Gilead Sciences Ireland UC, Rapporteur: Jean-Michel Race Request for Supplementary Information adopted on 13.01.2022.	

Ilumetri - tildrakizumab - EMEA/H/C/004514/II/0029/G Almirall S.A, Rapporteur: Jan Mueller-Berghaus	
Leqvio - inclisiran - EMEA/H/C/005333/II/0008 Novartis Europharm Limited, Rapporteur: Martina Weise Request for Supplementary Information adopted on 27.01.2022.	
Mylotarg - gemtuzumab ozogamicin - EMEA/H/C/004204/II/0023/G, Orphan Pfizer Europe MA EEIG, Rapporteur: Thalia Marie Estrup Blicher Opinion adopted on 10.03.2022. Request for Supplementary Information adopted on 27.01.2022.	Positive Opinion adopted by consensus on 10.03.2022.
Natpar - parathyroid hormone - EMEA/H/C/003861/II/0033/G, Orphan Takeda Pharmaceuticals International AG, Rapporteur: Karin Janssen van Doorn Request for Supplementary Information adopted on 02.12.2021.	
Natpar - parathyroid hormone - EMEA/H/C/003861/II/0035, Orphan Takeda Pharmaceuticals International AG, Rapporteur: Karin Janssen van Doorn Opinion adopted on 10.03.2022. Request for Supplementary Information adopted on 13.01.2022.	Positive Opinion adopted by consensus on 10.03.2022.
NUVAXOVID - sars-cov-2, spike protein, recombinant, expressed in sf9 cells derived from spodoptera frugiperda - EMEA/H/C/005808/II/0004 Novavax CZ, a.s., Rapporteur: Johann Lodewijk Hillege	
Odomzo - sonidegib - EMEA/H/C/002839/II/0041 Sun Pharmaceutical Industries Europe B.V., Rapporteur: Paula Boudewina van Hennik	
Ondexxya - andexanet alfa - EMEA/H/C/004108/II/0027 Alexion Europe SAS, Rapporteur: Jan Mueller-Berghaus	
Paxlovid - (1r,2s,5s)-n-((1s)-1-cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2s)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)	Request for supplementary information adopted with a specific timetable.

butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0001/G Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race Request for Supplementary Information adopted on 17.03.2022.	
Paxlovid - (1r,2s,5s)-n-((1s)-1-cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2s)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0002 Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race Opinion adopted on 17.03.2022.	Positive Opinion adopted by consensus on 17.03.2022.
Paxlovid - (1r,2s,5s)-n-((1s)-1-cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2s)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0003/G Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race Request for Supplementary Information adopted on 17.03.2022.	Request for supplementary information adopted with a specific timetable.
Pedea - ibuprofen - EMEA/H/C/000549/II/0030 Recordati Rare Diseases, Rapporteur: Jayne Crowe	
Polivy - polatuzumab vedotin - EMEA/H/C/004870/II/0014/G, Orphan Roche Registration GmbH, Rapporteur: Alexandre Moreau Request for Supplementary Information adopted on 03.02.2022.	
Regkirona - regdanvimab - EMEA/H/C/005854/II/0002 Celltrion Healthcare Hungary Kft., Rapporteur: Filip Josephson	
Ruconest - conestat alfa - EMEA/H/C/001223/II/0071 Pharming Group N.V, Rapporteur: Andrea Laslop Request for Supplementary Information adopted on 17.03.2022.	Request for supplementary information adopted with a specific timetable.
Spectrila - asparaginase - EMEA/H/C/002661/II/0026	

medac Gesellschaft fur klinische Spezialpraparate mbH, Rapporteur: Andrea Laslop Request for Supplementary Information adopted on 25.11.2021.	
Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0038/G Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 17.02.2022.	
Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0050 Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus	
Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0054/G Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus Opinion adopted on 10.03.2022.	Positive Opinion adopted by consensus on 10.03.2022.
Supemtek - quadrivalent influenza vaccine (recombinant, prepared in cell culture) - EMEA/H/C/005159/II/0007/G Sanofi Pasteur, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 10.03.2022.	Request for supplementary information adopted with a specific timetable.
Toviaz - fesoterodine - EMEA/H/C/000723/II/0065/G Pfizer Europe MA EEIG, Rapporteur: Maria Concepcion Prieto Yerro Opinion adopted on 03.03.2022. Request for Supplementary Information adopted on 20.01.2022.	Positive Opinion adopted by consensus on 03.03.2022.
TRODELVY - sacituzumab govitecan - EMEA/H/C/005182/II/0002/G Gilead Sciences Ireland UC, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 17.03.2022.	Positive Opinion adopted by consensus on 17.03.2022.
TRODELVY - sacituzumab govitecan - EMEA/H/C/005182/II/0003 Gilead Sciences Ireland UC, Rapporteur: Jan Mueller-Berghaus	Positive Opinion adopted by consensus on 17.03.2022.

Opinion adopted on 17.03.2022.	
Trulicity - dulaglutide - EMEA/H/C/002825/II/0062/G Eli Lilly Nederland B.V., Rapporteur: Martina Weise Opinion adopted on 17.03.2022.	Positive Opinion adopted by consensus on 17.03.2022.
Tysabri - natalizumab - EMEA/H/C/000603/II/0132 Biogen Netherlands B.V., Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 17.03.2022.	Request for supplementary information adopted with a specific timetable.
Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis b (rdna), poliomyelitis (inact.) and haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/003982/II/0095 MCM Vaccine B.V., Rapporteur: Christophe Focke Opinion adopted on 17.03.2022.	Positive Opinion adopted by consensus on 17.03.2022. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0062 AstraZeneca AB, Rapporteur: Sol Ruiz	
Xolair - omalizumab - EMEA/H/C/000606/II/0114 Novartis Europharm Limited, Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 13.01.2022.	
ZABDENO - ebola vaccine (rDNA, replication-incompetent) - EMEA/H/C/005337/II/0009/G Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 17.03.2022.	Request for supplementary information adopted with a specific timetable.
WS2159/G **Prolia- EMEA/H/C/001120/WS2159/0095/G** **XGEVA- EMEA/H/C/002173/WS2159/0079/G** Amgen Europe B.V., Lead Rapporteur: Kristina Dunder	
WS2218/G **Advate-**	Request for supplementary information adopted with a specific timetable.

EMEA/H/C/000520/WS2218/0115/G **ADYNOVI-** **EMEA/H/C/004195/WS2218/0029/G** Baxalta Innovations GmbH, Lead Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 17.03.2022.	
WS2225/G **Abseamed-** **EMEA/H/C/000727/WS2225/0097/G** **Binocrit-** **EMEA/H/C/000725/WS2225/0096/G** **Epoetin alfa Hexal-** **EMEA/H/C/000726/WS2225/0096/G** Sandoz GmbH, Lead Rapporteur: Alexandre Moreau	

B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Bimzelx - bimekizumab - **EMEA/H/C/005316/II/0002** UCB Pharma S.A., Rapporteur: Peter Kiely, "C.I.4 - Update of section 5.1 of the SmPC in order to update efficacy information based on interim results from study PS0015; this is a multicentre, randomized, double-blind, active comparator controlled, parallel group study to evaluate the efficacy and safety of bimekizumab compared with secukinumab in adult study participants with moderate to severe plaque psoriasis. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.2." Request for Supplementary Information adopted on 16.12.2021.	
Brilique - ticagrelor - **EMEA/H/C/001241/II/0054** AstraZeneca AB, Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning and new adverse drug reactions on bradyarrhythmia and AV blocks based on a review of all currently available information, including clinical trial data, post-marketing reports and plausible mechanism." Opinion adopted on 03.03.2022. Request for Supplementary Information adopted	Positive Opinion adopted by consensus on 03.03.2022.

on 14.10.2021.

Cyramza - ramucirumab - EMEA/H/C/002829/II/0043

Eli Lilly Nederland B.V., Rapporteur: Paula Boudewina van Hennik, "Update of section 4.4 of the SmPC in order to add a new warning on heart failure following a detailed cumulative review of post-marketing data. The Package Leaflet and Labelling are updated accordingly. In addition, the MAH took the opportunity to update the package leaflet to include hypothyroidism as a common side effect."
Request for Supplementary Information adopted on 16.12.2021.

Dapivirine Vaginal Ring 25 mg - dapivirine - EMEA/H/W/002168/II/0014/G

International Partnership for Microbicides Belgium AISBL, Rapporteur: Paula Boudewina van Hennik, "C.I.13: Submission of the study report from study MTN-020 (Version 2.0). This is a multicentre, randomized, double-blind, placebo-controlled Phase III safety and effectiveness trial of a vaginal matrix ring containing dapivirine for the prevention of HIV-1 infection in women.
C.I.13: Submission of the Clinical Virology Report (Version 4.0). This report describes virologic characterisation of virus from HIV-1 seroconversion events during double-blind, placebo-controlled, randomized, multicentre Phase III clinical trials evaluating the safety and efficacy of Dapivirine Vaginal Ring."
Request for Supplementary Information adopted on 13.01.2022.

Gardasil 9 - human papillomavirus vaccine [types 6, 11, 16, 18, 31, 33, 45, 52, 58] (recombinant, adsorbed) - EMEA/H/C/003852/II/0053

MSD Vaccins, Rapporteur: Kristina Dunder, "Update of section 5.1 of the SmPC in order to update long-term effectiveness and immunogenicity data following the final results of the Gardasil 9 long-term follow-up (LTFU) study V503-002-20 listed as a category 3 study in the RMP. In addition, the applicant took the opportunity to make some minor editorial changes (spacings) and included the updated long-term follow-up data received for the qHPV vaccine following V501-167 extension study.

The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 17.02.2022.	
Iclusig - ponatinib - EMEA/H/C/002695/II/0061, Orphan Incyte Biosciences Distribution B.V., Rapporteur: Filip Josephson, "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC based on results from the OPTIC study (AP24534-14-203) listed as a specific obligation in the Annex II. This is a randomised, open-label, Phase 2 trial of ponatinib in patients with chronic myeloid leukaemia to characterise the efficacy and safety of ponatinib over a range of doses; the Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 13.01.2022, 14.10.2021.	
Keytruda - pembrolizumab - EMEA/H/C/003820/II/0115 Merck Sharp & Dohme B.V., Rapporteur: Armando Genazzani, "Update of section 5.1 of the SmPC in order to update efficacy information based on final results from study KEYNOTE-426 listed as imposed PAES in the Annex II; this is a Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC)." Request for Supplementary Information adopted on 02.12.2021.	See 9.1
Mosquirix - plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted) - EMEA/H/W/002300/II/0060 GlaxoSmithkline Biologicals SA, Rapporteur: Jan Mueller-Berghaus, "Submission of the final study report from study Malaria-073, a Phase III, randomized, open-label, controlled and multicenter study that addressed two safety concerns listed in the RMP: immunogenicity when coadministered with yellow fever and measles vaccines, and cross-immunisation against human catalase. The submission of the study addresses MEA 004." Opinion adopted on 17.03.2022.	Positive Opinion adopted by consensus on 17.03.2022.

Orphacol - cholic acid - EMEA/H/C/001250/II/0044, Orphan Laboratoires CTRS, Rapporteur: Anastasia Mountaki, "Update of sections 4.3 and 4.5 of the SmPC in order to extend the currently existing contra-indication with phenobarbital in order to include primidone based on scientific literature. The Package Leaflet is updated accordingly. In addition, MAH is also taking this opportunity to submit a combined SmPC for both dosages, 50 mg and 250 mg and to introduce editorial changes and update the contact details of the local representatives in the Package Leaflet."	
Orphacol - cholic acid - EMEA/H/C/001250/II/0045, Orphan Laboratoires CTRS, Rapporteur: Anastasia Mountaki, "Update of section 4.5 of the SmPC in order update the existing information regarding concomitant use of cholic acid (the active substance of Orphacol) and ursodeoxycholic acid based on scientific literature. The Package Leaflet is updated accordingly."	
QINLOCK - ripretinib - EMEA/H/C/005614/II/0002, Orphan Deciphera Pharmaceuticals (Netherlands) B.V., Rapporteur: Filip Josephson, "Submission of the final report from study XT218029 (DP-4851: ABC Transporter Substrate Potential in Cells). This submission fulfils the PAM commitment "New in vitro experiment to study whether ripretinib is a substrate of BCRP, which follows the design outlined in appendix 3 of the DDI GL - October 2021-REC." Opinion adopted on 10.03.2022.	Positive Opinion adopted by consensus on 10.03.2022.
Retsevmo - selpercatinib - EMEA/H/C/005375/II/0010 Eli Lilly Nederland B.V., Rapporteur: Alexandre Moreau, "Update of sections 4.2 and 5.3 of the SmPC in order to reflect the need to monitor open growth plates in adolescent patients based on the results from a non-clinical juvenile toxicity study LOXO-292-TOX-028. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to correct figures in section 5.1 of the SmPC." Request for Supplementary Information adopted on 16.12.2021.	
Ronapreve - casirivimab / imdevimab -	Positive Opinion adopted by consensus on

EMEA/H/C/005814/II/0001 Roche Registration GmbH, Rapporteur: Jan Mueller-Berghaus, "Update of sections 4.1, 4.4 and 5.1 of the SmPC in order to update information on the in vitro neutralisation activity of casirivimab/imdevimab against the SARS-CoV-2 B.1.1.529 (Omicron) variant." Opinion adopted on 04.03.2022. Request for Supplementary Information adopted on 10.02.2022.	04.03.2022.
Tivicay - dolutegravir - EMEA/H/C/002753/II/0077 ViiV Healthcare B.V., Rapporteur: Filip Josephson, "Following the recommendation (REC) requested during the procedure EMA/H/C/2753/X/58G, the MAH submits the manuscript of the ODYSSEY study which contains efficacy and long-term safety results to 96 weeks for Tivicay tablets. This study an open-label, multicenter, randomized (1:1), non-inferiority, Phase II/III, 96-week, 2-arm clinical trial to compare the efficacy and toxicity of dolutrgravir (DTG) plus 2 NRTIs vs. standard of care in HIV infected children aged less than 18 years who are starting first-line ART (ODYSSEY A) or switching to second-line ART (ODYSSEY B). Based on the results no amendments to the product information for DTG (Tivicay) are considered warranted and therefore, no updated SmPC is provided as part of this application." Opinion adopted on 17.03.2022.	Positive Opinion adopted by consensus on 17.03.2022.
Toviaz - fesoterodine - EMEA/H/C/000723/II/0063 Pfizer Europe MA EEIG, Rapporteur: Maria Concepcion Prieto Yerro, "C.I.3 Update of sections 4.2, 5.1 and 5.2 of the SmPC with the results from study A0221047, to evaluate the safety and efficacy of fesoterodine in subjects aged 6 to 17 years with neurogenic detrusor overactivity. The change was suggested in the outcome of the EMEA/H/C/000723/P46/030.1. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 10.1." Request for Supplementary Information adopted	

on 14.10.2021.

Trogarzo - ibalizumab - EMEA/H/C/004961/II/0018

Theratechnologies Europe Limited, Rapporteur: Johann Lodewijk Hillege, "Update of section 5.1 of the SmPC in order to add additional efficacy data based on results from study TMB-311, a multicentre, expanded access phase 3 study providing post-hoc long-term data on patients from study TMB-301."

VITRAKVI - larotrectinib - EMEA/H/C/004919/II/0021

Bayer AG, Rapporteur: Filip Josephson, "Update of section 5.2 of the SmPC in order to reflect the outcome of an updated analysis of the population pharmacokinetic (PopPk) model based on additional PK sampling in patients aged 1 month to 6 years from study LOXO-TRK-15003 (SCOUT) imposed as a specific obligation (SOB). The MAH is also proposing to delete this SOB from Annex II. The MAH took the opportunity of this variation to introduce corrections to section 4.8 of the SmPC and to Annex II."
Request for Supplementary Information adopted on 02.12.2021.

Xarelto - rivaroxaban - EMEA/H/C/000944/II/0093

Bayer AG, Rapporteur: Kristina Dunder, "Update of section 5.1 and subsequent changes in sections 4.2 and 4.8. based on final results from study 18226 (UNIVERSE); this is a prospective, open-label, active controlled, multicentre, 2-part study, designed to evaluate the single- and multiple-dose pharmacokinetic properties of rivaroxaban (Part A), and to evaluate the safety and efficacy of rivaroxaban when used for thromboprophylaxis for 12 months compared with acetylsalicylic acid (Part B) in children 2 to 8 years of age with single ventricle physiology who had the Fontan procedure.
In addition, the MAH took the opportunity to introduce editorial changes to sections 4.8 and 4.9 of the SmPC."

Xtandi - enzalutamide - EMEA/H/C/002639/II/0058

Astellas Pharma Europe B.V., Rapporteur: Maria Concepcion Prieto Yerro, "Update of section 4.5

in order to add information regarding drug-drug interaction based on final results from study 9785-CL-0018 - A Phase 1 Open-label Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects with Prostate Cancer. Additionally, the MAH has taken the opportunity to make an update to the information about the excipients in section 4.4 of the SmPC, to introduce editorial changes in the SmPC and in the Package Leaflet, and to update the list of local representatives in the Package Leaflet."	
WS2174 **Hexacima-** **EMEA/H/C/002702/WS2174/0123** **Hexyon-** **EMEA/H/C/002796/WS2174/0127** Sanofi Pasteur Europe, Duplicate, Duplicate of Hexacima, Lead Rapporteur: Jan Mueller-Berghaus, "Update of section 4.5 of the SmPC in order to add drug-drug interaction information regarding the co-administration of Hexyon / Hexacima with varicella vaccines based on a re-analysis of the A3L15 clinical trial varicella serological data, submitted in the initial CTD dossier. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to correct some typo errors in the SmPC and PL." Request for Supplementary Information adopted on 20.01.2022.	
WS2183 **Infanrix hexa-** **EMEA/H/C/000296/WS2183/0310** GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke, "Update of sections 2 and 4.3 of the SmPC for Infanrix Hexa in order to remove the residue formaldehyde. The PL is updated accordingly. Moreover, these sections are also been updated for the removal of some residues currently mentioned in the Product Information (PI) of some of GSK's DTPa/dTpa combined vaccines (NAPs). In addition, the MAH took the opportunity to align the PI to the Annex to the European Commission guideline on "Excipients in the labelling and package leaflet of medicinal	

product for human use" (sections 2, 4.4 and 6.1 of the SmPC). The MAH also took the opportunity to introduce some additional minor changes to the PI and to update the list of local representatives in the Package Leaflet." Request for Supplementary Information adopted on 03.02.2022.	
WS2224 Eucreas-EMEA/H/C/000807/WS2224/0094 Galvus-EMEA/H/C/000771/WS2224/0075 Icandra-EMEA/H/C/001050/WS2224/0097 Jalra-EMEA/H/C/001048/WS2224/0077 Xiliarx-EMEA/H/C/001051/WS2224/0075 Zomarist-EMEA/H/C/001049/WS2224/0096 Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC in order to update the list of ADRs and update the ADR table in line with the EC SmPC guideline (2009). The Package Leaflet is updated accordingly."	

B.5.3. CHMP-PRAC assessed procedures

ADCETRIS - brentuximab vedotin - EMEA/H/C/002455/II/0099, Orphan Takeda Pharma A/S, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Menno van der Elst, "Update of sections 4.8 and 5.1 of the SmPC, based on final results from study C25006, a multicenter open-label, phase 4 study of 50 patients with r/r sALCL undertaken to further evaluate the efficacy and safety of brentuximab vedotin as a single agent in adult patients who had previously received at least 1 multiagent chemotherapy regimen. This study is listed as an interventional cat 2 PASS in the RMP (SOB 010). In addition, the MAH took the opportunity to delete SOB 010 from the annex II and to delete the mention of conditional approval from annex II and the package leaflet. The RMP version 16.1 has also been submitted."	
Afstyla - lonoctocog alfa - EMEA/H/C/004075/II/0042 CSL Behring GmbH, Rapporteur: Jan Mueller-	Request for supplementary information adopted with a specific timetable.

Berghaus, PRAC Rapporteur: Sonja Hrabcik, "Update of section 5.1 of the SmPC in order to update efficacy and safety information based on final results from study 3001 listed as a category 3 study in the RMP; this is a open label, multicentre extension study to assess the Safety and Efficacy of Afstyla in subjects with severe Haemophilia A. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. The RMP version 6.0 has also been submitted." Request for Supplementary Information adopted on 10.03.2022.	
ASPAVELI - pegcetacoplan - EMEA/H/C/005553/II/0002, Orphan Swedish Orphan Biovitrum AB (publ), Rapporteur: Alexandre Moreau, PRAC Rapporteur: Kimmo Jaakkola, "Update of sections 4.2, 4.8, 5.1, 5.2 of the SmPC based on final results from study APL2-302 (Pegasus) listed as a category 3 study in the RMP; this is a global, Phase 3, prospective, randomised, multicentre, open-label, active-comparator–controlled study in 80 subjects. The objective was to confirm treatment efficacy and safety of pegcetacoplan monotherapy for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The submission of this study addresses MEA 001. The Package Leaflet is updated accordingly. The RMP version 0.5 has also been submitted."	
Defitelio - defibrotide - EMEA/H/C/002393/II/0056, Orphan Gentium S.r.l., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, "Submission of the final report from study 15-007 listed as a specific obligation in the Annex II of the Product Information. This is a phase 3, randomised, adaptive study (15-007) of Defibrotide vs. best supportive care in the prevention of hepatic venoocclusive disease in adult and paediatric patients undergoing hematopoietic stem cell transplant (HSCT). The RMP version 9 has also been submitted. The MAH has also taken the opportunity to align the PI to the latest QRD template 10.2 which replaces the United Kingdom with United Kingdom (Northern Ireland) in the PIL. In addition, the MAH is correcting the following	Request for supplementary information adopted with a specific timetable. See 9.1

errata during the linguistic review of the PI: correction of the paragraph number for Regulation (EC) No 726.2004 which was cited incorrectly in Annex II of the French PI and formatting updates to Norwegian and Swedish language PIs." Request for Supplementary Information adopted on 10.03.2022, 28.10.2021, 08.07.2021.	
Dexdor - dexmedetomidine - EMEA/H/C/002268/II/0035 Orion Corporation, Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga, "Update of section 4.4 of the SmPC in order to add a new warning on Mortality in ICU patients ≤ 65 years old, based on results from study SPICE III (randomised controlled trial) and following the assessment of the post-authorisation measure LEG 16.4. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. The RMP version 9, a proposed DHPC and communication plan have also been submitted."	
Esperoct - turoctocog alfa pegol - EMEA/H/C/004883/II/0010, Orphan Novo Nordisk A/S, Rapporteur: Andrea Laslop, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of sections 4.4 and 4.8 of the SmPC to add a new warning and update the list of ADRs based on a validated safety signal concerning a lack of factor VIII activity in patients switching from a similar factor VIII product to Esperoct. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and to align it with the latest QRD template version 10.2. The RMP version 2.0 has also been submitted."	
Fintepla - fenfluramine - EMEA/H/C/003933/II/0010/G, Orphan Zogenix ROI Limited, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber, "- Update of section 5.3 of the SmPC in order to update the non-clinical information following the study 20147822 (A 6-month Carcinogenicity Study of Fenfluramine Hydrochloride in Mice). - Update of section 5.3 in order to update the non-clinical information following the study 8001993 (A 2-year Oral Gavage Carcinogenicity Study of Fenfluramine Hydrochloride in Rats).	Request for supplementary information adopted with a specific timetable.

- Submission of the final report of study 20147821 (Dose range finding study for 20147822). - Submission of the final report of study 20166554 (Dose range finding study for 20147822). - Submission of the final report of study 2021006-Z001-01 (In-vitro Evaluation of Potential Melanin Binding by Fenfluramine and Norfenfluramine). An RMP version 3.1 has also been submitted." Request for Supplementary Information adopted on 10.03.2022.	
Fintepla - fenfluramine - EMEA/H/C/003933/II/0011/G, Orphan Zogenix ROI Limited, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber, "- Update of sections 4.2 and 5.2 of the SmPC to include the relevant information regarding patients with renal impairment following the study 1902 (Pharmacokinetic study of fenfluramine hydrochloride in subjects with varying degrees of impaired and normal renal function). - Update of sections 4.4 and 4.5 of the SmPC in order to reflect the relevant information on CYP1A2 or CYP2B6 or CYP2D6 inducers following the study 1904 (Pharmacokinetic drug-drug interaction study of fenfluramine hydrochloride with and without fluvoxamine (CYP1A2 inhibitor), paroxetine (CYP2D6 inhibitor) and rifampin (CYP2B6 inducer) in healthy subjects). An RMP version 2.2 has also been submitted." Request for Supplementary Information adopted on 10.03.2022.	Request for supplementary information adopted with a specific timetable.
GIVLAARI - givosiran - EMEA/H/C/004775/II/0006, Orphan Alnylam Netherlands B.V., Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Martin Huber, "Type II C.I.4 : Update of SmPC section 4.8 to add 'blood homocysteine increase' as a new ADR and update to SmPC section 4.4 to add a related warning. The package leaflet is being updated accordingly. RMPv1.1 is also being submitted: consequences of blood homocysteine increase is being added as a new important potential risk, the clinical and post-marketing exposure is being updated and the due dates for ALN-AS1-002 and ALN-AS1-003	Request for supplementary information adopted with a specific timetable.

final study reports are being postponed.
In addition, the MAH took the opportunity to make editorial changes to the Product Information in other EU languages and to update the contact number of the local representatives for Malta and Cyprus."
Request for Supplementary Information adopted on 10.03.2022, 13.01.2022, 28.10.2021, 02.09.2021.

LUTATHERA - lutetium (177lu) oxodotreotide - EMEA/H/C/004123/II/0030, Orphan

Advanced Accelerator Applications, Rapporteur: Janet Koenig, PRAC Rapporteur: Adam Przybylkowski, "Update of the SmPC sections 4.4, 4.8 and 5.1 based on the pivotal Phase III study, NETTER-1. Additionally, updates are proposed in the PI to correct some information based on currently approved data. The PL is updated accordingly. The RMP v. 2.0 has been submitted. The MAH took also the opportunity to update the details of local representatives in the PL."
Request for Supplementary Information adopted on 16.12.2021.

MabThera - rituximab - EMEA/H/C/000165/II/0188

Roche Registration GmbH, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Anette Kirstine Stark, "Submission of the final report from study MA28150 (RITAZAREM) entitled Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophilcytoplasm antibody-associated vasculitis listed as an interventional category 3 study in the RMP.
The RMP version 23.0 has also been submitted."

Mekinist - trametinib - EMEA/H/C/002643/II/0051

Novartis Europharm Limited, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: David Olsen, "Update of sections 4.2 and 5.2 of the SmPC in order to change posology recommendations in hepatic impairment and update pharmacokinetic information based on final results from study MEC116354 listed as a category 3 study in the RMP; this is a Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients with Hepatic

Dysfunction. The RMP version 18 has also been submitted." Request for Supplementary Information adopted on 16.12.2021.	
Myalepta - metreleptin - EMEA/H/C/004218/II/0025, Orphan Amryt Pharmaceuticals DAC, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Adam Przybylkowski, "Submission of an updated RMP version 2.1. The applicant is proposing an alternative study to the currently agreed protocol for Specific Obligation SOB002 (AEGR-734-002) due to the challenges of implementing the existing protocol. Annex II is being updated accordingly. The MAH took the opportunity to update the RMP in line with the outcome of previous procedures and to include editorial changes."	
Mylotarg - gemtuzumab ozogamicin - EMEA/H/C/004204/II/0024, Orphan Pfizer Europe MA EEIG, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "Update of sections 4.8, 5.1 and 5.2 of the SmPC based on the final results from study B176103; this is a single-arm, open-label, phase 4 study evaluating the QT interval, pharmacokinetics, and safety of gemtuzumab ozogamicin as a single-agent regimen in patients with relapsed or refractory CD33-positive Acute Myeloid Leukaemia. The RMP version 2.0 has also been submitted. In addition, the MAH took the opportunity to introduce some editorial changes in the product information." Request for Supplementary Information adopted on 18.03.2022.	Request for supplementary information adopted with a specific timetable.
Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/II/0056 Orexigen Therapeutics Ireland Limited, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber, "Submission of updated study design and protocol synopsis for CVOT-2 study, a category 1 study listed in Annex II.D (ANX/001.7) undertaken to assess the effect of naltrexone extended release (ER) / bupropion ER on the occurrence of major adverse cardiovascular events (MACE), as requested in the CHMP AR for ANX/001.6. The	See 9.1

Annex II and the RMP version 13 are updated accordingly.”	
Pemazyre - pemigatinib - EMEA/H/C/005266/II/0005, Orphan Incyte Biosciences Distribution B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Menno van der Elst, “Update of sections 4.4, 4.8 and 5.1 of the SmPC based on the final results from study INCB054828 (FIGHT-202) listed as a specific obligation in the Annex II (SOB/002); this is a phase 2 study investigating the efficacy and safety of pemigatinib in adults with advanced/metastatic or surgically unresectable cholangiocarcinoma including FGFR2 translocations who failed previous therapy. The Annex II has been updated accordingly. RMP version 2.0 has also been submitted.”	
Piqray - alpelisib - EMEA/H/C/004804/II/0008/G Novartis Europharm Limited, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Menno van der Elst, “Update of section 5.1 of the SmPC based on final results from study CBYL719C2301 (SOLAR-1) listed as a PAES in the Annex II; this is a phase III, randomized, double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment; the Annex II is updated accordingly. In addition, the MAH is updating the ATC code in the SmPC. The RMP version 5.0 has also been submitted.” Request for Supplementary Information adopted on 28.10.2021.	See 9.1
Prolia - denosumab - EMEA/H/C/001120/II/0093 Amgen Europe B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, “Update of sections 4.2 and 4.4 of the SmPC in order to change the posology recommendation for paediatric population and add a new warning on hypercalcaemia in paediatric patients with osteogenesis imperfecta following an urgent safety measure regarding the risk of hypercalcaemia reported very commonly in ongoing clinical trials in paediatric patients with	

osteogenesis imperfecta (OI) treated with denosumab; the Package Leaflet is updated accordingly. The RMP version 29.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to implement minor editorial changes in the Labelling." Request for Supplementary Information adopted on 24.02.2022.	
Raxone - idebenone - EMEA/H/C/003834/II/0031, Orphan Santhera Pharmaceuticals (Deutschland) GmbH, Rapporteur: John Joseph Borg, PRAC Rapporteur: Amelia Cupelli, "Update of sections 4.2, 4.4, 4.9 and 5.1 of the SmPC based on the final study report from the PAROS study SNT-IV-003 (SOB003; listed as a cat 2 study in the RMP): "A non-interventional study of clinical experience in patients prescribed Raxone for the treatment of Leber's Hereditary Optic Neuropathy (LHON)". Annex II is updated in accordance. A revised RMP version 1.14 was also submitted."	See 9.1
Replagal - agalsidase alfa - EMEA/H/C/000369/II/0117 Shire Human Genetic Therapies AB, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan, "Update of sections 4.2 and 6.6 of the SmPC in order to add self-administration by a trained patient and/or a caregiver as a new method of administration. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI. The RMP version 0.1 has also been submitted."	
RINVOQ - upadacitinib - EMEA/H/C/004760/II/0015/G AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce, "Grouping of 2 variations: C.I.4 - Update of sections 4.8 to add neutropenia and 5.1 of the SmPC in order to update efficacy information of Rinvoq in Ankylosing Spondylitis (AS) patients who are biologic DMARD inadequate responders (bDMARD-IR) based on interim results from study M19-944 study 1; this is a Phase 3,	

randomized, double-blind, study evaluating the long-term safety, tolerability, and efficacy of upadacitinib 15 mg QD in subjects with active AS who have an inadequate response (IR) to bDMARD. C.I.4 - Update of section 5.1 of the SmPC in order to include long-term (through week 104) data in AS patients who are naïve to previous treatment with a bDMARD based on interim results from study M16-098; this is a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis; The RMP version 7.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes in the product information."	
Rubraca - rucaparib - EMEA/H/C/004272/II/0029 Clovis Oncology Ireland Limited, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Annika Folin, "Update of sections 4.4, 4.8 and 5.1 of the SmPC based on final results from study CO-338-043 (ARIEL4); this is a phase 3, multicentre, open-label, randomised study evaluating the efficacy and safety of rucaparib versus chemotherapy for treatment of relapsed ovarian cancer listed as a specific obligation in the Annex II; the Package Leaflet is updated accordingly. The RMP version 6.1 has also been submitted. With this variation application, the MAH requests for the Rubraca marketing authorisation to no longer be subject to specific obligations. The SmPC, Annex II and PL are updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes and bring the PI in line with the latest QRD template version 10.2 Rev.1." Request for Supplementary Information adopted on 11.11.2021.	See 9.1
Rydapt - midostaurin - EMEA/H/C/004095/II/0024, Orphan Novartis Europharm Limited, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "C.I.11.b Submission of the final report from study CPKC412E2301 listed as an obligation in the Annex II of the Product Information. This is	Request for supplementary information adopted with a specific timetable.

a Phase III study to investigate the efficacy in elderly patients. A final pharmacogenomic report is also provided to fulfil MEA004. The Annex II and the RMP (submitted version 7.0) are updated accordingly." Request for Supplementary Information adopted on 10.03.2022.	
Ryeqo - relugolix / estradiol / norethisterone acetate - EMEA/H/C/005267/II/0006 Gedeon Richter Plc., Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Martin Huber, "Submission of the final report from study MVT-601-035 listed as a category 3 study in the RMP. This is an international phase III double-blind, placebo-controlled, randomised withdrawal study of relugolix co-administered with estradiol and norethisterone in women with heavy menstrual bleeding associated with uterine fibroids to evaluate the efficacy and safety of long-term use of this medicinal product. The RMP version 1.0 has also been submitted." Opinion adopted on 10.03.2022.	Positive Opinion adopted by consensus on 10.03.2022.
WAYLIVRA - volanesorsen - EMEA/H/C/004538/II/0017/G, Orphan Akcea Therapeutics Ireland Limited, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber, "C.I.4: Update of sections 4.8 and 5.1 of the SmPC based on the final results from study (ISIS 304801 CS7), a multicentre open label extension study of Volanesorsen administered subcutaneously to patients with Familial Chylomicronemia Syndrome. The Package Leaflet has been updated accordingly. The RMP version 2.1 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the PI in order to align with the QRD template and to introduce minor linguistic update to Annex III of the product information to support product launch. C.I.11b. for RMP: Submission of an updated RMP version 2.1 based on the clinical study report addendum: A randomized, double blind, placebo-controlled Phase 3 study of ISIS 304801 administered subcutaneously to patients with Familial Chylomicronemia Syndrome (ISIS 304801 CS6 (APPROACH). C.I.11b. for RMP: Submission of an updated	Request for supplementary information adopted with a specific timetable.

RMP version 2.1 in order to update section V.2 Additional Risk Minimisation Measures in the RMP to reflect a change in the distribution methodology of the educational materials (from a centralised model to a localised model of distribution) and to clarify what is meant by the prescriber kit. C.I.13: Submission of the final report from study ISIS 304801 (CS17). This is a Phase 2/3 double blind, randomized, placebo-controlled study, with an open label extension of ISIS 304801 administered subcutaneously to patients with familial partial lipodystrophy. The RMP version 2.1 has also been submitted." Request for Supplementary Information adopted on 10.03.2022.	
Xtandi - enzalutamide - EMEA/H/C/002639/II/0057 Astellas Pharma Europe B.V., Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia, "C.I.4 Update of sections 4.8, 5.1 and 5.2 of the SmPC in order to reflect the updated safety and efficacy data from the final analysis of the 9785-CCL-0335 (ARCHES) study, a phase 3 randomized, double-blind, placebo-controlled study that evaluated the safety and efficacy of enzalutamide plus androgen deprivation therapy (ADT) vs placebo plus ADT in men with mHSPC; the Package Leaflet is updated accordingly. The RMP version 17.0 has also been submitted. In addition, the MAH took the opportunity to make minor editorial changes to section 4.8 and section 5.1 of the SmPC." Opinion adopted on 10.03.2022.	Positive Opinion adopted by consensus on 10.03.2022.

B.5.4. PRAC assessed procedures

PRAC Led **COMIRNATY - tozinameran - EMEA/H/C/005735/II/0087** BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of an updated RMP version 2.6 to include data from the booster/third dose, including data in patients who have undergone a solid organ transplantation, following the	Positive Opinion adopted by consensus on 10.03.2022.

outcomes of procedures EMEA/H/C/005735/II/0062 (third dose in immunocompromise as part of the primary vaccination) and EMEA/H/C/005735/II/0067 (booster dose). The MAH takes the opportunity to update the RMP regarding the discontinuation of enrolment in study C4591015 (phase 2/3 study to evaluate the safety, tolerability, and immunogenicity in healthy pregnant women 18 years of age and older) and the CSR milestones." Opinion adopted on 10.03.2022. Request for Supplementary Information adopted on 13.01.2022.	
PRAC Led **Cyramza - ramucirumab - EMEA/H/C/002829/II/0047** Eli Lilly Nederland B.V., Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Submission of the final report from study I4T-MC-JVDD listed as a category 3 study in the RMP for Cyramza, entitled 'Safety and Effectiveness of Ramucirumab in Patients with Advanced Gastric Cancer in the European Union and North America: A Prospective Observational Registry (Study I4T-MC-JVDD)' (Related to MEA 001.1). The RMP version 10.1 has also been submitted." Opinion adopted on 10.03.2022.	Positive Opinion adopted by consensus on 10.03.2022.
PRAC Led **Hemlibra - emicizumab - EMEA/H/C/004406/II/0025** Roche Registration GmbH, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Amelia Cupelli, PRAC-CHMP liaison: Armando Genazzani, "Update of sections 4.4, 4.8 and 5.1 of the Product information concerning immunogenicity and loss of efficacy due to anti-emicizumab antibodies. The RMP (v.4.1) is proposed to be updated accordingly." Opinion adopted on 10.03.2022. Request for Supplementary Information adopted on 13.01.2022, 02.12.2021, 02.09.2021.	Positive Opinion adopted by consensus on 10.03.2022.
PRAC Led **Hemlibra - emicizumab - EMEA/H/C/004406/II/0028** Roche Registration GmbH, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Amelia	Positive Opinion adopted by consensus on 10.03.2022.

Cupelli, PRAC-CHMP liaison: Armando Genazzani, "Submission of the final study report for BO40853 (Hemlibra Survey to Prescribers and Patients/Carers to Evaluate Awareness, Knowledge, and Compliance to Additional Risk Minimisation Measures, listed as a category 3 study in the RMP). An updated RMP (version 4.0) is presented in support of this application." Opinion adopted on 10.03.2022. Request for Supplementary Information adopted on 13.01.2022, 02.12.2021.	
PRAC Led **Inflectra - infliximab - EMEA/H/C/002778/II/0105** Pfizer Europe MA EEIG, Duplicate, Duplicate of Remsima, Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kimmo Jaakkola, PRAC-CHMP liaison: Outi Mäki-Ikola, "Submission of the final report from study CT-P13 4.2; An Observational, Prospective Cohort Study to Evaluate Safety and Efficacy of Inflectra in Patients with Rheumatoid Arthritis (study report excluding the joint analysis of patients in the PERSIST study). The submission of the study report addresses MEA 007.6." Opinion adopted on 10.03.2022.	Positive Opinion adopted by consensus on 10.03.2022.
PRAC Led **Kuvan - sapropterin - EMEA/H/C/000943/II/0073** BioMarin International Limited, Rapporteur: Peter Kiely, PRAC Rapporteur: Rhea Fitzgerald, PRAC-CHMP liaison: Peter Kiely, "Submission of the final report from study BMN 162-501 KAMPER (formerly EMR700773-001) listed as a category 3 study in the RMP. This is an observational drug registry to assess the long-term safety in subjects treated with Kuvan. The submission of this study addresses the PAM MEA 020. The RMP version 15.1 has also been submitted." Request for Supplementary Information adopted on 10.03.2022.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Latuda - lurasidone - EMEA/H/C/002713/II/0037** Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A., Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Filip Josephson, "Submission of	Positive Opinion adopted by consensus on 10.03.2022.

an updated RMP version 9.0, based on the implementation of the PASS outcome (EMEA/H/C/002713/II/0033), to remove from the list of safety concerns of important identified risks and important potential risks; and to discontinue the use of targeted adverse event follow-up questionnaire for angioedema." Opinion adopted on 10.03.2022.	
PRAC Led **Moventig - naloxegol - EMEA/H/C/002810/II/0038** Kyowa Kirin Holdings B.V., Rapporteur: Christophe Focke, PRAC Rapporteur: Rhea Fitzgerald, PRAC-CHMP liaison: Peter Kiely, "Submission of an updated RMP version 7.2 proposing the cancellation of the cat. 3 study (D3820R00009: An Observational Drug Utilisation PASS of Moventig in selected European populations), following the assessment of MEA 006.11" Request for Supplementary Information adopted on 10.03.2022.	Request for supplementary information adopted with a specific timetable.
PRAC Led **PecFent - fentanyl - EMEA/H/C/001164/II/0054** Kyowa Kirin Holdings B.V., Rapporteur: Janet Koenig, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, "Submission of an updated RMP (version 7.1) in line with the outcome of the last PSUR single assessment (PSUSA) procedure (PSUSA 00001369/202004) finalised in January 2021 in order to update the key messages of the educational materials in line with Instanyl (fentanyl). As a result, Annex II-D on 'Conditions or restrictions with regard to the safe and effective use of the medicinal product' is updated accordingly. Finally, the MAH took the opportunity to bring the RMP in line with revision 2 of GVP module V on 'Risk management systems' and the product information in line with the latest quality review of documents (QRD) template (version 10.2). The requested variation proposed amendments to the Annex II and to the Risk Management Plan (RMP)." Request for Supplementary Information adopted on 10.03.2022, 28.10.2021.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Praluent - alirocumab -**	Request for supplementary information adopted with a specific timetable.

EMEA/H/C/003882/II/0068 sanofi-aventis groupe, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Update of section 4.8 of the SmPC, based on the final results from category 3 study OBS14697; a non-interventional, retrospective drug utilisation study that was designed to assess in Europe the effectiveness of the dosing recommendation and to describe patterns of alirocumab utilisation in real world clinical practice. In addition, the MAH took the opportunity to implement editorial changes in SmPC and package leaflet. The submission of the study report addresses the Post-Authorisation Measure MEA/FSR 019.8." Request for Supplementary Information adopted on 10.03.2022.	
PRAC Led **Remsima - infliximab - EMEA/H/C/002576/II/0111** Celltrion Healthcare Hungary Kft., Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kimmo Jaakkola, PRAC-CHMP liaison: Outi Mäki-Ikola, "Submission of the final report from study CT-P13 4.2; An Observational, Prospective Cohort Study to Evaluate Safety and Efficacy of Remsima in Patients with Rheumatoid Arthritis (study report excluding the joint analysis of patients in the PERSIST study)." Opinion adopted on 10.03.2022.	Positive Opinion adopted by consensus on 10.03.2022.
PRAC Led **Tegsedi - inotersen - EMEA/H/C/004782/II/0026, Orphan** Akcea Therapeutics Ireland Limited, Rapporteur: Martina Weise, PRAC Rapporteur: Rhea Fitzgerald, PRAC-CHMP liaison: Peter Kiely, "Updated RMP version 3.1 removes carcinogenicity in rats as missing information, adds a targeted questionnaire as routine pharmacovigilance measure and a patient alert card as additional risk minimisation for liver transplant rejection. Adds 'injection site reactions' and 'immunogenicity' as risks not considered important for inclusion in the summary of safety concerns (SVII.1.) and updates the patient alert card with additional warnings on hepatic monitoring and ocular toxicity. Further sections of the RMP are	Positive Opinion adopted by consensus on 10.03.2022.

updated." Opinion adopted on 10.03.2022. Request for Supplementary Information adopted on 13.01.2022.	
PRAC Led **XALKORI - crizotinib - EMEA/H/C/002489/II/0075** Pfizer Europe MA EEIG, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, PRAC-CHMP liaison: Alexandre Moreau, "Submission of the final report for non-interventional PASS cat 3 study A8081062, a descriptive study of potential sight threatening event and severe visual loss following exposure to crizotinib (related to MEA 024)." Request for Supplementary Information adopted on 10.03.2022.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Zepatier - elbasvir / grazoprevir - EMEA/H/C/004126/II/0033** Merck Sharp & Dohme B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ana Sofia Diniz Martins, PRAC-CHMP liaison: Bruno Sepodes, "Submission of the final report from study B20-146 listed as a category 3 study in the RMP. This is a non-imposed joint post-authorisation safety study to evaluate the risk of de novo hepatocellular carcinoma in patients with compensated cirrhosis treated with direct-acting antivirals for chronic hepatitis C (HCC De Novo PASS)." Request for Supplementary Information adopted on 10.03.2022.	Request for supplementary information adopted with a specific timetable.
PRAC Led **WS2210** **Dovato-EMEA/H/C/004909/WS2210/0028** **Juluca-EMEA/H/C/004427/WS2210/0041** **Tivicay-EMEA/H/C/002753/WS2210/0076** **Triumeq-EMEA/H/C/002754/WS2210/0100** ViiV Healthcare B.V., Lead Rapporteur: Filip Josephson, Lead PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Ingrid Wang, "Following the finalisation of procedure EMEA/H/C/WS1810 concerning submission of EuroSIDA (category 3 PASS) study, this Type II worksharing variation was proposed to address the removal of three important risks (Dolutegravir Hypersensitivity reactions,	Positive Opinion adopted by consensus on 10.03.2022.

Hepatobiliary reactions and Serious rash) from all four dolutegravir-containing product EU-RMPs; Tivicay (dolutegravir), Triumeq (dolutegravir/abacavir/lamivudine), Dovato (dolutegravir/lamivudine) and Juluca (dolutegravir/rilpivirine) - i.e. deletion of safety concerns. In addition, the MAH took opportunity to propose a harmonisation of the risks across all four dolutegravir-containing product EU-RMPs and other minor updates (including study details and epidemiology data). The requested worksharing procedure proposed amendments to the Risk Management Plan (RMP).” Opinion adopted on 10.03.2022.	
PRAC Led **WS2212** **Effentora-** **EMEA/H/C/000833/WS2212/0060** Teva B.V., Lead Rapporteur: Janet Koenig, Lead PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, “Submission of an updated RMP version 5.1 in order to reformat the RMP according to the revised guidance on GVP Module V (revision 2) and to implement PRAC comments arising from previous assessments as follows: - Revision of the list of safety concerns; - Implementation of key messages in educational materials adopted by PRAC for Instanyl; - Revision of Annex 6 to include verbatim the text adopted by PRAC for Instanyl as presented in Annex 2 of the PRAC PSUSA AR; - Revision of the use of digital access to educational material; - Explanation of the role of the Health Products Regulatory Authority (HPRA)'s CAPA being no longer found to be a trigger of the current RMP update. The 'additional risk minimisation measures' in the Annex II of the product information have been updated accordingly.” Request for Supplementary Information adopted on 10.03.2022.	Request for supplementary information adopted with a specific timetable.
PRAC Led **WS2214** **Duloxetine Mylan-**	Positive Opinion adopted by consensus on 10.03.2022.

EMEA/H/C/003981/WS2214/0029 Mylan Pharmaceuticals Limited, Generic, Generic of Cymbalta, Lead PRAC Rapporteur: Maria del Pilar Rayon, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "To update the RMP in order to align with the originator. The MAH has taken the opportunity to amend the RMP template GVP Module V Rev.2, where required, and to achieve one RMP covering multiple different marketing authorisations procedures containing the same active substance for which Mylan has an approved RMP. The RMP is also updated with the results of a follow-up questionnaire pertaining to suicidality as recommended in the Renewal EMEA/H/C/003981/R/0021." Opinion adopted on 10.03.2022.	
PRAC Led **WS2216** **Exviera-EMEA/H/C/003837/WS2216/0052** **Maviret-EMEA/H/C/004430/WS2216/0049** **Viekirax-EMEA/H/C/003839/WS2216/0064** AbbVie Deutschland GmbH & Co. KG, Lead Rapporteur: Filip Josephson, Lead PRAC Rapporteur: Ana Sofia Diniz Martins, PRAC-CHMP liaison: Bruno Sepodes, "Submission of the final report from study B20-146 listed as a category 3 study in the RMP. This is a non-imposed joint post-authorisation safety study to evaluate the risk of de novo hepatocellular carcinoma in patients with compensated cirrhosis treated with direct-acting antivirals for chronic hepatitis C (HCC De Novo PASS)." Request for Supplementary Information adopted on 10.03.2022.	Request for supplementary information adopted with a specific timetable.
PRAC Led **WS2222** **Epclusa-EMEA/H/C/004210/WS2222/0064** **Harvoni-EMEA/H/C/003850/WS2222/0104** **Sovaldi-EMEA/H/C/002798/WS2222/0077** **Vosevi-EMEA/H/C/004350/WS2222/0054** Gilead Sciences Ireland UC, Lead Rapporteur: Filip Josephson, Lead PRAC Rapporteur: Ana Sofia Diniz Martins, PRAC-CHMP liaison: Bruno	Request for supplementary information adopted with a specific timetable.

Sepodes, "Submission of the final report from study B20-146 listed as a category 3 study in the RMP. This is a non-imposed joint post-authorisation safety study to evaluate the risk of de novo hepatocellular carcinoma in patients with compensated cirrhosis treated with direct-acting antivirals for chronic hepatitis C (HCC De Novo PASS)." Request for Supplementary Information adopted on 10.03.2022.

B.5.5. CHMP-CAT assessed procedures

Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0048, ATMP Amgen Europe B.V., Rapporteur: Maija Tarkkanen, CHMP Coordinator: Johanna Lähteenvuo, "Update of section 4.4 of the SmPC in order to add a new warning about the potential risk of hepatic haemorrhage with the transcutaneous intrahepatic route of administration of talimogene laherparepvec. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet."
Tecartus - autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured - EMEA/H/C/005102/II/0016, Orphan, ATMP Kite Pharma EU B.V., Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus Request for Supplementary Information adopted on 21.01.2022.
Zolgensma - onasemnogene abeparvovec - EMEA/H/C/004750/II/0020/G, Orphan, ATMP Novartis Gene Therapies EU Limited, Rapporteur: Carla Herberts, CHMP Coordinator: Johann Lodewijk Hillege Request for Supplementary Information adopted on 10.12.2021.
Zolgensma - onasemnogene abeparvovec - EMEA/H/C/004750/II/0024, Orphan,

ATMP Novartis Gene Therapies EU Limited, Rapporteur: Carla Herberts, CHMP Coordinator: Johann Lodewijk Hillege

B.5.6. CHMP-PRAC-CAT assessed procedures

B.5.7. PRAC assessed ATMP procedures

Strimvelis - autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence - EMEA/H/C/003854/II/0033, Orphan, ATMP Orchard Therapeutics (Netherlands) BV, Rapporteur: Sol Ruiz, CHMP Coordinator: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Menno van der Elst, "Submission of the final report from study STRIM-001 "Evaluation of referring healthcare providers' and parents'/carers' understanding of specific risks associated with Strimvelis treatment" listed as a category 3 study in the RMP. The RMP version 6.1 has also been submitted."

B.5.8. Unclassified procedures and work-sharing procedures of type I variations

WS2171 **Glyxambi-** **EMEA/H/C/003833/WS2171/0040** **Synjardy-** **EMEA/H/C/003770/WS2171/0058** Boehringer Ingelheim International GmbH, Lead Rapporteur: Johann Lodewijk Hillege, "To update section 4.8 of the SmPC and section 4 of the PL to include the side effect 'constipation' in order to align with the Jardiance PI following approval of EMEA/H/C/002677/II/0055." Request for Supplementary Information adopted on 03.02.2022, 02.12.2021.	
WS2220/G **Cymbalta-** **EMEA/H/C/000572/WS2220/0088/G** **Duloxetine Lilly-** **EMEA/H/C/004000/WS2220/0025/G** **Yentreve-** **EMEA/H/C/000545/WS2220/0073/G**	Positive Opinion adopted by consensus on 10.03.2022.

Eli Lilly Nederland B.V., Duplicate, Duplicate of Ariclaim (SRD), Yentreve, Lead Rapporteur: Maria Concepcion Prieto Yerro Opinion adopted on 10.03.2022.	
WS2221/G **Eucreas-** **EMEA/H/C/000807/WS2221/0093/G** **Galvus-** **EMEA/H/C/000771/WS2221/0074/G** **Icandra-** **EMEA/H/C/001050/WS2221/0096/G** **Jalra-** **EMEA/H/C/001048/WS2221/0076/G** **Xiliarx-** **EMEA/H/C/001051/WS2221/0074/G** **Zomarist-** **EMEA/H/C/001049/WS2221/0095/G** Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder	
WS2228 **Eucreas-** **EMEA/H/C/000807/WS2228/0095** **Icandra-** **EMEA/H/C/001050/WS2228/0098** **Zomarist-** **EMEA/H/C/001049/WS2228/0097** Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder	

B.5.9. Information on withdrawn type II variation / WS procedure

WS2120 **Nuwiq-EMEA/H/C/002813/WS2120/0045** **Vihuma-** **EMEA/H/C/004459/WS2120/0027** Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 16.12.2021, 02.09.2021. Withdrawal request submitted on 09.03.2022.	The MAH withdrew the procedure on 09.03.2022.
Feraccru - ferric maltol - **EMEA/H/C/002733/II/0033** Norgine B.V., Rapporteur: Maria Concepcion Prieto Yerro, "to remove haemoglobin threshold from section 4.4 'Special warnings and precautions for use' of summary of product characteristics for Feraccru Capsules 30 mg,	The MAH withdrew the procedure on 01.03.2022.

deleting the reference made that states "Feraccru is not recommended for use in patients with haemoglobin (Hb) <9.5 g/dl." Request for Supplementary Information adopted on 03.02.2022, 21.10.2021, 22.07.2021. Withdrawal request submitted on 01.03.2022.	

B.5.10. Information on type II variation / WS procedure with revised timetable

Uptravi - selexipag - EMEA/H/C/003774/II/0034 Janssen-Cilag International N.V., Rapporteur: Martina Weise, PRAC Rapporteur: Nathalie Gault, "Update of section 4.8 of the SmPC to add 'dyspepsia' as a new ADR with frequency 'common', and to include further information on the frequency of 'dyspepsia' and 'anaemia' specific to initial 2-step triple combination therapy, based on the studies AC-065A308 (TRITON) and AC-065A404 (TRACE). AC-065A308 (TRITON) study was a randomized, double-blind, placebo-controlled, parallel-group, Phase 3b, efficacy and safety study comparing triple oral combination therapy (selexipag, macitentan, tadalafil) with double oral combination therapy (placebo, macitentan, tadalafil) in newly diagnosed, treatment-naïve participants with PAH. The AC-065A404 (TRACE) study was a randomized, double-blind, placebo-controlled, parallel-group, exploratory Phase 4 study in participants with PAH to assess the effect of selexipag on daily life physical activity and participant's self-reported symptoms and their impacts. The package leaflet is updated accordingly. A revised RMP version 9.2 was provided as part of the application." Request for Supplementary Information adopted on 02.12.2021.	Request by the applicant for an extension to the clock stop to respond to the RSI adopted in December 2021.

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

tixagevimab / cilgavimab - EMEA/H/C/005788 prophylaxis of COVID-19 in adults 18 years of age and older	See also 3.1

B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

Calquence - acalabrutinib - EMEA/H/C/005299/X/0009/G
AstraZeneca AB, Rapporteur: Filip Josephson, PRAC Rapporteur: Željana Margan Koletić, "Extension application to introduce a new pharmaceutical form, film-coated tablet. A.6 - To change the ATC Code of acalabrutinib from L01XE51 to L01EL02."
List of Questions adopted on 24.02.2022.

mobocertinib - EMEA/H/C/005621
Treatment of adult patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
List of Questions adopted on 11.11.2021.

lutetium (177lu) chloride - EMEA/H/C/005859
It is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with Lutetium (177Lu) chloride.
List of Questions adopted on 16.12.2021.

voclosporin - EMEA/H/C/005256
indicated in combination with background immunosuppressive therapies for the treatment of adult patients with class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN).
List of Questions adopted on 11.11.2021.

octreotide - EMEA/H/C/005826, Orphan
FGK Representative Service GmbH, treatment of acromegaly
List of Questions adopted on 16.12.2021.

relatlimab / nivolumab - EMEA/H/C/005481
indicated for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents (12 years and older and weighing at least 40 kg).

List of Questions adopted on 27.01.2022.

pemetrexed - EMEA/H/C/005848
treatment of malignant pleural mesothelioma and non-small cell lung cancer
List of Questions adopted on 16.12.2021.

valoctocogene roxaparvovec - EMEA/H/C/005830, Orphan, ATMP
BioMarin International Limited, treatment of severe haemophilia A
List of Questions adopted on 05.11.2021.

thalidomide - EMEA/H/C/005715
treatment of multiple myeloma
List of Questions adopted on 16.09.2021.

faricimab - EMEA/H/C/005642
treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DME)
List of Questions adopted on 14.10.2021.

bevacizumab - EMEA/H/C/005534
Treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer.
First-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer.
First line treatment of patients with advanced and/or metastatic renal cell cancer.
List of Questions adopted on 24.02.2022.

olipudase alfa - EMEA/H/C/004850, Orphan
Genzyme Europe BV, treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in paediatric and adult patients
List of Questions adopted on 22.02.2022.

B.6.4. Annual Re-assessments: timetables for adoption

B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

AYVAKYT - avapritinib -
EMEA/H/C/005208/R/0017, Orphan
Blueprint Medicines (Netherlands) B.V.,
Rapporteur: Blanca Garcia-Ochoa, PRAC
Rapporteur: Menno van der Elst

VITRAKVI - larotrectinib -
EMEA/H/C/004919/R/0024
Bayer AG, Rapporteur: Filip Josephson, PRAC
Rapporteur: Rugile Pilviniene

B.6.6. VARIATIONS – START OF THE PROCEDURE

Timetables for adoption provided that the validation has been completed.

B.6.7. Type II Variations scope of the Variations: Extension of indication

Veklury - remdesivir -
EMEA/H/C/005622/II/0035/G
Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, PRAC Rapporteur: Eva Jirsová,
"Grouped application of two Extensions of indication to include:
- treatment of paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) or other non-invasive ventilation at start of treatment, based on interim results from study GS-US-540-5823; a phase 2/3 single-arm, open-label study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of Remdesivir in participants from birth to <18 years of age with COVID-19;
- treatment of paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID 19, based on data from 8 adolescent patients who were included in study GS-US-540-9012, which was initially assessed by the CHMP as part of procedure II/16 (Extension of Indication to include treatment of adults).
As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet as well as the instructions for healthcare professionals have been updated accordingly. Version 3.2 of the RMP has also

been submitted."

B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

Benepali - etanercept -
EMEA/H/C/004007/II/0063/G
Samsung Bioepis NL B.V., Rapporteur: Andrea Laslop

COMIRNATY - tozinameran -
EMEA/H/C/005735/II/0116/G
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson

COMIRNATY - tozinameran -
EMEA/H/C/005735/II/0120/G
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson

COMIRNATY - tozinameran -
EMEA/H/C/005735/II/0121/G
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson

Darzalex - daratumumab -
EMEA/H/C/004077/II/0059/G, Orphan
Janssen-Cilag International N.V., Rapporteur: Thalia Marie Estrup Blicher

Elaprase - idursulfase -
EMEA/H/C/000700/II/0098/G
Shire Human Genetic Therapies AB, Rapporteur: Johann Lodewijk Hillege

Fasturtec - rasburicase -
EMEA/H/C/000331/II/0063/G
sanofi-aventis groupe, Rapporteur: Johann Lodewijk Hillege

IMCIVREE - setmelanotide -
EMEA/H/C/005089/II/0005/G, Orphan
Rhythm Pharmaceuticals Netherlands B.V., Rapporteur: Karin Janssen van Doorn

Increlex - mecasermin -
EMEA/H/C/000704/II/0076
Ipsen Pharma, Rapporteur: Outi Mäki-Ikola

Ngenla - somatrogon -
EMEA/H/C/005633/II/0001/G, Orphan
Pfizer Europe MA EEIG, Rapporteur: Peter Kiely

NUVAXOVID - sars-cov-2, spike protein, recombinant, expressed in sf9 cells derived

from spodoptera frugiperda -
EMEA/H/C/005808/II/0004
Novavax CZ, a.s., Rapporteur: Johann Lodewijk Hillege

Oncaspar - pegaspargase -
EMEA/H/C/003789/II/0045/G
Les Laboratoires Servier, Rapporteur: Alexandre Moreau

Privigen - human normal immunoglobulin -
EMEA/H/C/000831/II/0185
CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus

ReFacto AF - moroctocog alfa -
EMEA/H/C/000232/II/0163/G
Pfizer Europe MA EEIG, Rapporteur: Thalia Marie Estrup Blicher

Rixubis - nonacog gamma -
EMEA/H/C/003771/II/0044
Baxalta Innovations GmbH, Rapporteur: Andrea Laslop

Shingrix - herpes zoster vaccine (recombinant, adjuvanted) -
EMEA/H/C/004336/II/0053
GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke

Voraxaze - glucarpidase -
EMEA/H/C/005467/II/0002, Orphan
SERB S.A.S., Rapporteur: Ondřej Slanař

WS2231
Ambirix-
EMEA/H/C/000426/WS2231/0121
Twinrix Adult-
EMEA/H/C/000112/WS2231/0156
Twinrix Paediatric-
EMEA/H/C/000129/WS2231/0157
GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke

WS2232/G
Infanrix hexa-
EMEA/H/C/000296/WS2232/0314/G
GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke

WS2252
Prolia-EMEA/H/C/001120/WS2252/0096
XGEVA-EMEA/H/C/002173/WS2252/0080
Amgen Europe B.V., Lead Rapporteur: Kristina

Dunder

B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Adakveo - crizanlizumab - EMEA/H/C/004874/II/0007, Orphan Novartis Europharm Limited, Rapporteur: Daniela Philadelphy, "Update of section 5.2 of the SmPC in order to update pharmacokinetic information based on the results from PK reanalysis. In addition, the MAH took the opportunity to introduce minor editorial changes to the SmPC."
Avonex - interferon beta-1a - EMEA/H/C/000102/II/0192 Biogen Netherlands B.V., Rapporteur: Maria Concepcion Prieto Yerro, "Update of section 4.4 of the SmPC in order to add a new warning regarding the risk of injection site necrosis based on post-marketing experience. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet."
Biktarvy - bictegravir / emtricitabine / tenofovir alafenamide - EMEA/H/C/004449/II/0047 Gilead Sciences Ireland UC, Rapporteur: Jean-Michel Race, "Update of sections 4.8 and 5.1 of the SmPC in order to include efficacy and safety data for antiretroviral therapy (ART)-naive adults based on final results from interventional studies GS-US-380-1489 (A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir /Dolutegravir /Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults) and GS-US-380-1490 (A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults). In addition, the MAH took this opportunity to introduce some minor administrative updates."

IMCIVREE - setmelanotide - EMEA/H/C/005089/II/0006, Orphan

Rhythm Pharmaceuticals Netherlands B.V., Rapporteur: Karin Janssen van Doorn, "Submission of the final report from study RM-493-011 "Setmelanotide (RM-493) Treatment Trial in Patients with Rare Genetic Disorders of Obesity". This is a Phase 2, open-label, uncontrolled, non-randomized study with an additional long-term safety extension. The primary objective was to assess changes in body weight within each patient population with rare genetic disorders of obesity (POMC, LEPR, BBS and AS) following 3-months of setmelanotide treatment."

INREBIC - fedratinib - EMEA/H/C/005026/II/0010/G, Orphan

Bristol-Myers Squibb Pharma EEIG, Rapporteur: Paula Boudewina van Hennik, "Update of section 4.4 of the SmPC in order to add new warnings on major adverse cardiac events (MACE), thrombosis and secondary malignancies. The updates pertain to three signals, assessed by the FDA, which were identified with another JAK inhibitor (tofacitinib) indicated in rheumatoid arthritis; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

JEMPERLI - dostarlimab - EMEA/H/C/005204/II/0009

GlaxoSmithKline (Ireland) Limited, Rapporteur: Blanca Garcia-Ochoa, "Type Type II (C.I.4) - To update section 6.6 of the SmPC to provide additional finished product administration instructions. The Package Leaflet is updated accordingly. In addition, the Applicant took the opportunity to correct a typographical error from SmPC section 5.1 Pharmacodynamic properties."

Luminity - perflutren - EMEA/H/C/000654/II/0039

Lantheus EU Limited, Rapporteur: Peter Kiely, "Update of section 4.4 of the SmPC in order to add a new warning on sickle cell anaemia, and update of section 4.8 of the SmPC to include the new ADRs Kounis Syndrome, sickle cell anaemia and vaso-occlusive crisis based on reports in the post-marketing setting.

The Package Leaflet is updated accordingly.”
Orladeyo - berotralstat - EMEA/H/C/005138/II/0006 BioCryst Ireland Limited, Rapporteur: Peter Kiely, “Update of sections 4.4 and 4.5 of the SmPC in order to remove the warning for women of childbearing potential and amend drug-drug interaction information with desogestrel based on final results from study BCX7353-111; this is a phase 1 drug interaction study to evaluate the effects of berotralstat on the pharmacokinetics of a combination oral contraceptive, desogestrel with ethinyl estradiol; the Package Leaflet is updated accordingly.”
Samsca - tolvaptan - EMEA/H/C/000980/II/0046/G Otsuka Pharmaceutical Netherlands B.V., Rapporteur: Armando Genazzani, “Update of section 4.5 of the SmPC in order to include information on the transporter substrates P-glycoprotein, BCRP and OCT1 upon request by PRAC following the assessment of PSUSA/00002994/202105 based on final results from the drug-drug interaction studies 156-201-00233 and 156-201-00234 (to align with the Jinarc PI); the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.”
Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0057 Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, “Update of section 4.2 of the Spikevax SmPC to include a 50 µg booster dose for adolescents 12 to 18 years of age, based on the extrapolation of safety and efficacy data from young adults (18 to 24 years of age). The package leaflet is updated accordingly.”
Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0059 Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, “To update Annex IIE of the Spikevax Product Information to delete SOB 001 & SOB 002. The latest data to complete the characterisation of the active substance and

finished product manufacturing processes (SOB 001) and to confirm the consistency of the active substance and finished product manufacturing process (initial and final scales) (SOB 002) have already been submitted and assessed in the context of previous procedures, and are now considered fulfilled."	
Tygacil - tigecycline - EMEA/H/C/000644/II/0121 Pfizer Europe MA EEIG, Rapporteur: Blanca Garcia-Ochoa, "Update of section 5.1 of the SmPC in order to reflect updated breakpoint tables regarding antimicrobial susceptibility testing (EUCAST). In addition, the MAH is taking the opportunity to update section 4.6 of the SmPC to remove reference to "pharmacodynamic/toxicological" data and update the contact details of the local representatives in the Package Leaflet."	
Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0052 AstraZeneca AB, Rapporteur: Sol Ruiz, "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to introduce a booster dose of Vaxzevria (homologous or heterologous) based on interim immunogenicity and safety data from the pivotal study D7220C00001, a partially double-blinded, randomised, multinational, active-controlled phase II/III clinical study and supportive literature evidence from studies COV001, RHH-001, COV-BOOST and Com-COV studies. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes/corrections throughout the product information."	
Veltassa - patiromer - EMEA/H/C/004180/II/0029 Vifor Fresenius Medical Care Renal Pharma France, Rapporteur: Jayne Crowe, "Update of sections 4.2 and 4.5 of the SmPC in order to introduce new drug-drug interaction information based on results from four in vitro studies: RLY-TR-0174, titled "In Vitro Evaluation of Potential RLY5016S and Immunosuppressant Drug-Drug Interactions"; RLY-TR-0184 (titled "In Vitro Evaluation of Potential Drug-Drug Interactions Between Patiromer and Sevelamer	

Hydrochloride"); "In Vitro Evaluation of Drug-Drug Interactions of commonly prescribed renal and cardiovascular Drugs with Patiromer DS" and "Drug-drug interactions of commonly prescribed renal and cardiovascular Drugs with Patiromer DS in a simulated GI tract passage study". The Package Leaflet is updated accordingly."	
Vidaza - azacitidine - EMEA/H/C/000978/II/0057 Bristol-Myers Squibb Pharma EEIG, Rapporteur: Paula Boudewina van Hennik, "Update of section 4.2 of the SmPC in order to include a statement advising health care professionals not to interchange azacitidine formulations (injectable versus oral), and update section 4.6 of the SmPC to revise the recommended duration of contraception use for women and men. The Package Leaflet is updated accordingly."	
VPRIV - velaglucerase alfa - EMEA/H/C/001249/II/0054, Orphan Takeda Pharmaceuticals International AG, Rapporteur: Martina Weise, "Submission of the final report from study SHP-GCB-402: a multicenter, open-label, single-arm, phase 4 study designed to prospectively evaluate the effects of VPRIV on bone-related pathology in treatment-naïve subjects with type 1 Gaucher disease."	
Vyxeos liposomal - daunorubicin / cytarabine - EMEA/H/C/004282/II/0030, Orphan Jazz Pharmaceuticals Ireland Limited, Rapporteur: Johanna Lähteenvuo, "Update of sections 4.2, 4.4 and 5.2 of the SmPC to amend information and delete the existing warning for patients with renal impairment based on the final results from study CPX351-102 (PMR2): a phase 1, open-label, PK and safety study to evaluate the potential impact of renal impairment on the pharmacokinetics and safety of CPX-351 (Daunorubicin and Cytarabine) liposome for injection treatment in adult patients with hematologic malignancies."	
WS2244 **Nuwiq-EMEA/H/C/002813/WS2244/0048** **Vihuma-EMEA/H/C/004459/WS2244/0030**	

Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus, "Update of sections 4.8 and 5.1 of the SmPC in order to add safety and efficacy data based on the final CSR from the category 3 study GENA-21b; a prospective, open-label, multicentre phase 3b study to assess the efficacy and safety of personalized prophylaxis with Human-cl rhFVIII in previously treated adult patients with severe haemophilia A. Further, upon request by the CHMP following the assessment of study GENA-05 (P46 013 and P46 014), the MAH is updating the numbers of evaluated subjects in SmPC section 4.8 and is removing of the sentence "A prospective open-label clinical study in PUPs with severe haemophilia A (<1% FVIII:C) is ongoing" in section 5.1 of the SmPC. The Package Leaflet is updated accordingly."	
WS2250 **Prezista-** **EMEA/H/C/000707/WS2250/0116** **Rezolsta-** **EMEA/H/C/002819/WS2250/0046** **Symtuza-** **EMEA/H/C/004391/WS2250/0043** Janssen-Cilag International N.V., Lead Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.3 and 4.5 of the SmPC in order to update the safety information based on final results from study TMC114FD1HTX1002; this is an interventional phase 1, 2-Panel, Fixed-Sequence, Open-Label Single-Center Study to Assess the Effect of Single and Multiple Doses of Darunavir in Combination with Cobicistat or Ritonavir on the Pharmacokinetics of Single Dose Dabigatran Etexilate in Healthy Participants. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce editorial changes in order to update the contact details of the local representatives in the Package Leaflet."	
WS2253 **Eucreas-** **EMEA/H/C/000807/WS2253/0096** **Galvus-EMEA/H/C/000771/WS2253/0076** **Icandra-** **EMEA/H/C/001050/WS2253/0100** **Jalra-EMEA/H/C/001048/WS2253/0078** **Xiliarx-EMEA/H/C/001051/WS2253/0077**	

Zomarist-
EMEA/H/C/001049/WS2253/0098
Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder, Lead PRAC Rapporteur: Annika Folin, "Update of section 4.8 of the SmPC in order to add the new ADRs 'cutaneous vasculitis'."

B.6.10. CHMP-PRAC assessed procedures

B.6.11. PRAC assessed procedures

PRAC Led
HEPLISAV B - hepatitis B surface antigen -
EMEA/H/C/005063/II/0014
Dynavax GmbH, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Submission of the final report from study (HBV25) listed as a category 3 PASS study in the RMP. This is a post-marketing observational surveillance study comparing the occurrence of Acute Myocardial Infarction (AMI) in recipients of HEPLISAV-B with recipients of another hepatitis B vaccine. As a consequence, the RMP version 1.2 has also been submitted, in which the MAH proposes the removal of AMI as an important potential risk from the list of safety concerns."

PRAC Led
Lemtrada - alemtuzumab -
EMEA/H/C/003718/II/0041
Sanofi Belgium, Duplicate, Duplicate of Lemtrada (WD), PRAC Rapporteur: Anette Kirstine Stark, PRAC-CHMP liaison: Thalia Marie Estrup Blicher, "Submission of an updated RMP version 10.0 in order to include the new important identified risk "Autoimmune Encephalitis" and to introduce changes in accordance to the rapporteurs' requests received as part of procedure EMEA/H/C/003718/II/0038."

PRAC Led
Myozyme - alglucosidase alfa -
EMEA/H/C/000636/II/0090
Genzyme Europe BV, PRAC Rapporteur: Nathalie Gault, PRAC-CHMP liaison: Alexandre Moreau, "Submission of the final report from non-

interventional PASS Pompe Safety Sub-Registry - AGLU06909/LTS13930. This final study report is submitted to address the assessment report conclusion of the Pompe registry report 2020 (MEA024.15 and MEA025.15 Annual Pompe Registry Report 2020)."

PRAC Led
Uptravi - selexipag - EMEA/H/C/003774/II/0035
Janssen-Cilag International N.V., PRAC Rapporteur: Nathalie Gault, PRAC-CHMP liaison: Alexandre Moreau, "Submission of an updated RMP version 9.3 in order to include the amendment of the ongoing EXPOSURE study protocol, to add the EXTRACT study (67896049PAH0002) as an additional pharmacovigilance activity (PASS) and to include the update of the PRAC-approved EDUCATE PASS protocol (assessed in EMEA/H/C/003774/MEA/003.4)."

B.6.12. CHMP-CAT assessed procedures

Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0050, ATMP
Amgen Europe B.V., Rapporteur: Maija Tarkkanen, CHMP Coordinator: Johanna Lähteenvuo

Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0052/G, ATMP
Amgen Europe B.V., Rapporteur: Maija Tarkkanen, CHMP Coordinator: Johanna Lähteenvuo

Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0053, Orphan, ATMP
Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang, "Submission of the final report from study CCTL019H2301 (BELINDA) listed as an obligation in the Annex II of the Product Information. This is a randomized open-label parallel-group multicenter Phase III trial to evaluate the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory B-cell aggressive NHL after failure of rituximab and anthracycline containing first-line immune-chemotherapy. The Annex II is

updated accordingly."

WS2247
Tecartus-
EMEA/H/C/005102/WS2247/0020
Yescarta-
EMEA/H/C/004480/WS2247/0050
Kite Pharma EU B.V., Lead Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus

B.6.13. CHMP-PRAC-CAT assessed procedures

B.6.14. PRAC assessed ATMP procedures

PRAC Led
Imlygic - talimogene laherparepvec -
EMEA/H/C/002771/II/0051, ATMP
Amgen Europe B.V., PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Submission of the final report from study 20180062; "Observational Research Study Report (ORSR)" listed as a category 3 study in the RMP. This is a multinational, non-interventional, cross-sectional survey study for the Patients aged ≥ 18 years who have received IMLYGIC at least once in the 3 months prior to completing the survey to evaluate the effectiveness of the patient-directed aRMMS. The primary objective of this study is to evaluate patients' knowledge levels of the key messages included in the IMLYGIC Patient Safety Brochure among patients who receive IMLYGIC."

B.6.15. Unclassified procedures and worksharing procedures of type I variations

WS2227
Esperoct-
EMEA/H/C/004883/WS2227/0011
NovoEight-
EMEA/H/C/002719/WS2227/0040
Novo Nordisk A/S, Lead Rapporteur: Jan Mueller-Berghaus

WS2237
Copalia HCT-
EMEA/H/C/001159/WS2237/0098
Dafiro HCT-

EMEA/H/C/001160/WS2237/0100
Exforge HCT-
EMEA/H/C/001068/WS2237/0097
Novartis Europharm Limited, Lead Rapporteur: Thalia Marie Estrup Blicher, "To update sections 4.4 and 4.8 of the SmPC in line with assessment of a PSUSA/00001662/202101 procedure on hydrochlorothiazide/spironolactone regarding the risk of acute respiratory distress syndrome (ARDS) linked to hydrochlorothiazide. The Package Leaflet has been updated in accordance."

WS2239/G
Hexacima-
EMEA/H/C/002702/WS2239/0128/G
Hexyon-
EMEA/H/C/002796/WS2239/0132/G
Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus

WS2240
HyQvia-EMEA/H/C/002491/WS2240/0077
Kiovig-EMEA/H/C/000628/WS2240/0116
Baxalta Innovations GmbH, Lead Rapporteur: Jan Mueller-Berghaus

B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY

B.7.1. Yearly Line listing for Type I and II variations

B.7.2. Monthly Line listing for Type I variations

B.7.3. Opinion on Marketing Authorisation transfer (MMD only)

B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)

B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)

B.7.6. Notifications of Type I Variations (MMD only)

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)

E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

E.1. Timetables – starting & ongoing procedures: For information

PMF timetables starting and ongoing procedures	Tabled in MMD and sent by post mail (folder E).

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

G.2. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

G.2.1. List of procedures concluding at 21-24 March 2022 CHMP plenary:

G.2.2. List of procedures starting in March 2022 for April 2022 CHMP adoption of outcomes

H. ANNEX H - Product Shared Mailboxes – e-mail address